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ABSTRACT 
The human placenta of different gestational ages is a readily available source for 
isolation of adult mesenchymal stem cell (MSC) for potential use in regenerative 
therapies. The chorionic villous region, the largest component of a placenta that 
interfaces with the maternal circulation, is a rich source of placental MSCs 
(PMSCs). To remain multipotent, PMSCs are best maintained in culture 
conditions that mimic the in vivo microenvironment. Insulin like growth factors 
(IGFs, IGF-I and -II) and oxygen tension are two of the most important 
microenvironmental factors in the placenta. They are of low concentration or 
tension respectively, at early gestation, and increase as pregnancy progresses. 
In this thesis, we investigated the role and cellular mechanisms by which IGFs 
and low oxygen tension determine PMSC fate. The main hypothesis is that the 
interaction between IGFs and oxygen tension determines PMSC fate towards 
self-renewal or differentiation. We used cell proliferation assay, immunoblotting, 
real-time PCR, and cell monolayer staining to evaluate the role of IGF and 
oxygen tension on PMSC multipotency and differentiation. We found that low 
oxygen tension was a major determinant of PMSCs proliferation and 
multipotency, and to delay differentiation. Also, PMSC response to IGF 
stimulation and low oxygen tension was gestational age dependent — preterm 
PMSCs being more multipotent and proliferative than term PMSCs. IGF-I and 
IGF-II promoted PMSC proliferation and multipotency via IGF-IR or IR, 
depending on oxygen tension. IGFs enhanced PMSC differentiation towards the 
osteogenic lineage which was transduced by ERK1/2 and AKT signaling 
 iii 
cascades. We conclude that IGFs and oxygen tension act synergistically or 
antagonistically, mimicking in vivo microenvironmental conditions, to determine 
PMSC fate towards multipotency or differentiation. The appropriate combination 
of IGFs and oxygen tension can be used to maintain stem cells in multipotency, 
or to be induced towards a specific progenitor cell lineage for successful use in 
tissue regeneration therapies. 
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INTRODUCTION 
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1.1. Stem Cell Origin  
1.1.1. Stem cell classification and potency 
Stem cells are naïve unspecialized clonal cells that have the capacity for self-
renewal and differentiation (1). Cells from an early embryo (e.g. morula) have the 
greatest potential to differentiate and can give rise to the whole embryo or 
organism, including germ cells and extraembryonic tissues. Most stem cells are 
derived from later gestation embryos and are classified according to their 
differentiation potential into pluripotent, multipotent, oligopotent and unipotent 
cells. Also, stem cells are classified according to their origin and derivation 
procedure into embryonic (ESCs), adult mesenchymal (MSCs), tissue-resident 
and induced pluripotent stem cells (iPSCs), where the first three are naturally 
occurring and are found in vivo, while the latter are generated in vitro from 
reprogramming terminally differentiated cells. ESCs are pluripotent, isolated from 
the inner cell mass of the blastocyst and can differentiate into any cell type of the 
three germ layers; adult MSCs are multipotent stem cells and have a limited 
proliferation capacity and a more restricted differentiation lineage (2). Recently, 
the development of iPSCs, as autologous ES-like cells that can be an alternative 
to allogeneic ESCs for tissue regeneration therapies, has generated much 
excitement. They are developed by somatic cell nuclear transfer (somatic 
nucleus transfer into anuclear oocyte) or reprogramming (using a combination of 
4 transcription factor OCT4, SOX2, KLF4, c-MYC, NANOG, and microRNA 
binding protein LIN28) (2-4).  
3 
 
 
  
The three transcription factors OCT4, SOX2 and NANOG are major regulatory 
triad of human ES cell fate and major transcription factors that are induced to 
develop iPSCs (3-6). Each of these transcription factors has a major role in 
repressing the differentiation process towards a specific lineage: OCT4 
represses extraembryonic and epiblast-derived lineages, SOX2 represses 
mesendoderm differentiation and NANOG represses embryonic ectoderm 
differentiation (5). Among the three transcription factors, OCT4 is the only 
indispensible transcription factor to generate iPSCs, and its transfection into 
neural progenitor cells as a single factor is sufficient to generate iPSCs (3, 4, 7-
9). OCT4, a POU homeodomain transcription factor, is regarded as the master 
regulator and gatekeeper of pluripotency to keep stem cells in an undifferentiated 
state (8, 10-12). For this critical role in maintaining pluripotency, OCT4 
expression is tightly regulated, whereas under- or over-expression leads to 
differentiation (10). Also, OCT4 is not lost in committed lineage progenitor cells of 
the three germ layers beyond gastrulation suggesting that it plays an important 
role in the commitment of pluripotent stem cells into somatic lineages (8). Indeed, 
pluripotent ESCs/iPSCs with low OCT4 levels fail to exit the pluripotent state 
upon the induction of differentiation, and were rescued to differentiate into three 
germ layers by the restoration of OCT4 expression (13).  
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1.1.2. Adult mesenchymal stem cells 
Mesenchymal stem cells (MSCs) or adult mesenchymal stem cells are 
multipotent cells that have the capacity for self-renewal and differentiation into 
different cell types of one or more lineages of three germ layers. The first 
discovery of the existence of multipotent stem cell population was by Till and 
McCulloch in 1961 (14), which was followed by the first bone marrow MSCs 
isolated in 1968 by Friedenstein (15). To date, MSCs have been isolated from 
every mature organ and tissue including skeletal muscle (16), adipose tissue 
(17), deciduous teeth (18), umbilical cord blood (19), peripheral blood (20), brain 
(21), etc. Several biological markers characterize stem cells of different origins, 
and are positive for CD73, CD105, CD117, CD29, CD44, CD71, CD90, CD106, 
CD120a, and CD124, and negative for hematopoietic markers CD34, CD45 and 
CD14 (22-24). It has been demonstrated that MSCs have the potential to 
differentiate into several major mesodermal cells including osteogenic, 
chondrogenic, adipogenic (25) and endothelial (26) cells, and ectodermal cells, 
including neuronal cells (27) in a microenvironment-dependent manner.  
 
1.2. Human Placenta – A Source of Stem Cells 
1.2.1. Placental development and the fetal compartment 
The human chorioallantoic placenta is the main organ that supports fetal growth 
and survival by offering nutrient supply and eliminating waste products (28). The 
optimal growth and development of the placenta is essential, and any 
5 
 
 
  
abnormality in development is responsible for many pregnancy complications 
including miscarriages, preterm birth, preeclampsia and fetal growth restriction 
(FGR) (28, 29). In a normal pregnancy, the human placenta is developed as 
single organ in which maternal and fetal compartments are brought together, and 
is delivered after the delivery of the baby at term gestation.  
 
The chorionic villi are the functional units of the placenta where 
oxygen/nutrient/waste exchange occurs between the uteroplacental and 
fetoplacental circulations without intermixing of blood. Each chorionic villus is 
composed of three layers: villous trophoblast (syncytiotrophoblasts/ 
cytotrophoblasts), villous stroma (mesenchymal cells/Hofbauer cells/fibroblasts), 
and fetal vascular endothelium (vascular smooth muscle cells/ perivascular 
cells/endothelial cells) (30). Trophoblasts are the first cells to be in direct contact 
with the maternal uterine environment, and therefore play a critical role in 
preventing an immune rejection of the conceptus and facilitating implantation. To 
form placental blood supply, trophoblasts invade the decidua and remodel spiral 
arteries in the uterus (28-30). By 10-12 weeks of gestation, maternal blood flows 
from the spiral arteries to fill up the intervillous space surrounding the villi for 
oxygen/nutrient/waste exchange. The stromal layer of the chorionic villous is a 
rich source of mesenchymal stem cells (MSCs), available for vasculogenesis and 
angiogenesis, and is located between the syncytiotrophoblasts/cytotrophoblasts 
layer that is in direct contact with maternal blood and the fetal endothelium that is 
in direct contact with fetal circulation (30). Also within the stromal layer, Hofbauer 
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cells, the antigen-presenting macrophages, are abundantly present to maintain 
host defense as they lie closely to cytotrophoblast cells and fetal endothelial cells 
(31). Fetal derived endothelial cells, surrounded by pericytes, form the capillary 
network of the chorionic villi. These pericytes play a significant role in blood 
vessel regeneration and are therefore important to maintain micro-vessel integrity 
and stability (30). Overall, the placenta’s vital role in supporting fetal development 
is to offer the embryo and fetus an optimal environment for growth and 
development. 
 
1.2.2. Stem cell populations in the placenta 
Placenta is a readily available, non-invasive and ethically less controversial 
source of adult mesenchymal stem cells (MSCs). These stem cells have been 
isolated successfully from the umbilical cord blood, umbilical cord, amniotic fluid, 
fetal membranes and placental tissue (chorion) (32). Placental MSCs were also 
isolated from the tissues of maternal origin, the decidua basalis and the decidua 
parietalis (32). Although, MSCs can be isolated from fetal or maternal tissues, 
placental MSCs are fetal in origin, and have the ability to expand at a higher 
proliferation rate and passage number in vitro than bone marrow MSCs (32), the 
more common MSC used in tissue regeneration therapies.   
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1.2.3. Placental mesenchymal stem cells (PMSCs) from chorionic villi 
In this thesis, placental mesenchymal stem cells (PMSCs) were isolated from the 
chorionic villi (33) (Fig. 1.1). PMSCs originate from a single cell population from 
the extraembryonic mesoderm of the developing totipotent fertilized egg, which 
invades the chorionic villous core along with cytotrophoblasts at 21 days post 
conception (33-35). These PMSCs play an important role early in placental 
vasculogenesis and angiogenesis as they differentiate into four cell types: 
macrophage-like mesenchymal cells (Hofbauer cells), haemangioblastic cords 
(multipotent precursor of hematopoietic and endothelial cells), pericytes (can be 
precursors of vascular endothelial cells) and stromal fibroblasts (34). These 
PMSCs are isolated from early and late gestation placentae (Fig. 1.1), using 
mechanical and enzymatic digestion with trypsin, collagenase and DNase (36) 
followed by Percoll density gradient separation similar to hematopoietic MSC 
isolation (37). PMSCs proliferate for at least up to 10 passages without alteration 
of phenotype and morphology in vitro, and have differentiation potential for all 
mesodermal lineages (adipogenic, chondrogenic, osteogenic, skeletal 
myogenic), ectodermal lineages (neuronal), and endodermal lineage (beta cells) 
(33). These cells are promising candidates for tissue regeneration therapy for 
their availability, abundance, ease of processing, and wide range of 
differentiation lineages. However, optimal culture conditions are required to 
maintain prolonged proliferation and maintenance of pluripotency and complete 
homogeneous differentiation in vitro. This can be achieved by understanding the 
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in vivo microenvironment of the placenta, and thereby, developing in vitro culture 
conditions that mimic in vivo conditions. 
 
1.3. Stem Cell Microenvironment   
1.3.1. Physical compartment 
Stem cell microenvironment or “niche” is an anatomical structure, including 
cellular and acellular components, that integrates local and systemic factors to 
regulate stem cell pluri- or multi-potency, proliferation, differentiation, survival and 
localization (Fig. 1.2) (38). Proliferation and differentiation of stem cells are 
maintained by the surrounding microenvironment via several clues including 
physical, structural, neural, humoral, paracrine, autocrine, and metabolic 
interactions (39). Therefore, a combination of different microenvironmental 
signals would determine the proliferative state of stem cells depending on the 
active process of tissue regeneration causing either cell proliferation or 
quiescence (40). In addition, the components present in the microenvironment, 
such as growth factors, cytokines, extracellular matrix, chemokines and oxygen 
levels, are critical for limiting or facilitating the MSC survival and propagation of 
stem cells (symmetric division) or differentiation to more specialized committed 
cells (asymmetric division).  
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Figure 1.2.  Stem cell niche in vivo. The stem cell niche is a complex 
compartment surrounding stem cells directing their identity preservation via 
cellular and acellular components. Various clues are exchanged between cells, 
extracellular matrix, growth factors, soluble factors and oxygen tension to direct 
the stemness state depending on growth and regeneration demand. Among 
growth factors, IGFs are derived via either paracrine or endocrine sources. 
Oxygen tension supplied by blood circulation is usually low in stem cell niches. 
IGFs and low oxygen tension alone or in combination may be major determinants 
of stem cell fate.  
Reproduced from Nature Reviews Molecular Cell Biology 9, Jones L and Wagers 
AJ. No place like home: anatomy and function of the stem cell niche. Pages12 
Copyright 2008, with permission from Nature Publishing Group. 
IGFs
IGFs
Low 
Oxygen 
Tension
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1.3.2. Oxygen tension and growth factor modulation 
Low oxygen tension in the stem cell microenvironment is being recognized as an 
important signal that regulates stem cell proliferation and differentiation (41). The 
notion of considering stem cell culture under room air (20% oxygen) in a cell 
culture incubator as “normoxia”, compared with a decreased ambient oxygen as 
“hypoxia”, has to be changed as oxygen tension in natural niches is low and 
termed “physiologic normoxia” (42). Oxygen tension, in many organs and tissues, 
ranges from 2-9% (14-65 mmHg) (43). In particular, oxygen levels reach 1.5-8% 
O2 in the mammalian reproductive tract, 1-2% O2 in bone marrow, and ~3% O2 in 
adipose tissue (41). Therefore, maintaining stem cells in low oxygen tension in 
vitro is more physiological than 20% O2 (room air condition) used in standard cell 
culture. Low oxygen tension can increase the rate of MSC proliferation and 
potentiate or diminish differentiation (depending on the differentiation lineage); 
and also a hypoxic preconditioning of MSC can improve engraftment and survival 
for transplantation (44).  
 
Besides its direct effect on maintaining on undifferentiated state, low oxygen 
tension can alter growth factor expression and secretion. Recently, MSCs were 
described as “medicinal secretory cells” that increase the secretion of trophic 
factors and immunomodulatory cytokines offering a regenerative 
microenvironment for injured tissues (45). Low oxygen tension is shown to 
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increase MSC gene expression and secretion of several factors involved in cell 
growth and survival including FGF2, HGF, VEGF-D, PGF, PBEF1, HB-EGF and 
MMP9 (46). IGF-I is another growth factor synthesized by MSCs, which induces 
an anti-apoptotic and pro-survival signals (47). Therefore, in ischemic or hypoxic 
tissues, MSCs are recruited by secreted cytokines and chemokines modulate 
survival, growth and angiogenesis, and facilitate recovery and repair of injured 
tissues. Hence, MSCs are increasingly recognized as important candidates for 
tissue regeneration either by direct differentiation or by supporting the repair 
mechanism to correct organ physiology and function — where low oxygen 
tension plays a significant role.  
 
1.3.3. Growth factor signaling 
In the stem cell niche, a combination of growth factor signaling inputs can control 
the stem cell state between proliferation and differentiation. In one study, the 
signaling of TGFβ/activin/nodal was required to maintain an undifferentiated state 
of hESCs (48). Another study showed that IGF-II and its signaling via the IGF-IR 
are important to maintain self-renewal and pluripotency in vitro with a 
requirement of bFGF/FGF-2 to maintain a supportive fibroblast cell population 
(49). The expression and signaling of many RTKs, such as FGFR1-3, EGFR 
(ERBB2 and ERBB3), VEGFR2, KIT, RET, and the IGF-IR, are important for 
stem cell multipotency and fate changes (50), where significant signaling 
cascades, yet to be elucidated, can maintain stem cell character. For application 
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in tissue regeneration, the use of xeno-free and animal-free cell culture 
conditions are desired to eliminate rejection and an immune response. For this, 
knock-out serum replacement (KOSR) media is becoming a preference for 
culture of ESCs, supplemented with growth factors to maintain pluripotency (51). 
Growth factors used in combination with KSOR media, including but are not 
limited to, bFGF/FGF2, activin A, HRG1, IGF-II and IGF-I (51).  
 
In addition to a combination of growth factor signaling required for stem cell 
pluripotency, the extracellular matrix (ECM) complex (e.g. matrigel) or a single 
component, (e.g. fibronectin, laminin, collagen, etc.) is used to support a feeder-
free culture of hESCs (51). One of the benefits of the ECM is in facilitating stem 
cell attachment and spreading, therefore enhancing cell proliferation and 
migration (52). Also, the extracellular matrix in stem cell niches can act as 
reservoir of growth factors to regulate their bioavailability and generate a gradient 
important to direct stem cell proliferation vs. differentiation (53). In the neural 
stem cell niche, heparan sulfate proteoglycans are shown to capture and 
concentrate FGF-2 from the milieu to support neural stem cell function (54). Also, 
in the ECM, integrins function cooperatively with signaling pathways to mediate 
receptor transactivation, coordination, modulation and receptor 
compartmentalization (53). For example, a crosstalk occurs between the IGF-IR 
and β1-integrin to modulate cell proliferation, migration and differentiation (52). 
Therefore, growth factor signaling can be manipulated by the stem cell niches. 
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By deconstructing the stem cell niche, the individual role of signaling pathways – 
such as the IGF axis – will need to be delineated.  
 
1. 3.4. Placental microenvironment changes during gestation stages 
1.3.4.1 Oxygen tension 
Oxygen tension and growth factor availability in the microenvironment of the 
developing human placenta continually change throughout gestation. The human 
conceptus requires low oxygen tension for healthy implantation into the external 
layer of the endometrium (55). Moreover, low oxygen tension is maintained 
during the first 10 days post-fertilization until trophoplasts develop and dip their 
processes in the maternal-blood. The placental tissue develops further and the 
oxygen level fluctuates in both maternal (endometrium) and fetal sides. At 8-10 
weeks of gestation, oxygen tension is very low, on the average of 17.9 mm Hg or 
2.35% O2 on the fetal side, which is lower than the maternal side at 39.6 mm Hg 
or (5.21% O2) (Fig. 1.3). Later, at 12-13 weeks of gestation the oxygen tension 
rises to reach 60.7 mm Hg or (7.98% O2) at the fetal side compared with 46.5 
mm Hg or (6.12% O2) at the maternal side (Fig. 1.3) (56). This change between 
the first and second trimester occurs due to the rise in the oxygen tension (PO2) 
at the intervillous space (IVS) which is facilitated by the active arterial blood flow 
between the IVS and the spiral arteries with low vascular resistance (55). Thus, 
the human embryo exists in a low oxygen environment, at least in the first 
trimester (0-12 weeks), when organogenesis occurs, indicating a major role for 
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Figure 1.3. Low oxygen tension and IGF levels in the placental 
microenvironment during gestation. Oxygen tension and IGF concentration are 
constantly changing during gestation. Low oxygen tension starts at near anoxic 
levels during implantation and rises upon the placental growth and connection 
with the maternal spiral arteries to reach 60 mmHg at early gestation and is 
maintained through gestation thereafter. IGF-I is expressed around 12 weeks of 
gestation, while IGF-II is expressed earlier at 6 weeks. Both IGF expression 
gradually increases during gestation. At term gestation, IGF-I concentration is 
100 ng/mL and IGF-II, 300 ng/mL, as measured in the umbilical cord blood. 
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low oxygen tension during development (55). Therefore, studying the behavior of 
placental mesenchymal stem cells (PMSCs) isolated at different gestation times 
(preterm vs. term) would unravel some aspects of placental development from 
the low oxygen tension microenvironment in the first trimester, to a well 
vascularized oxygenated tissue at the end of the third trimester (Fig. 1.3). 
 
1.3.4.2. Insulin-like growth factors  
Insulin-like growth factors (IGFs - IGF-I and IGF-II) represent one of the most 
important growth factor systems in cell growth and development, and cell-fate 
changes through several mitogen activation cascades (57-60). IGFs have a 
prominent role in pregnancy and fetal development by promoting proliferation, 
differentiation and survival of various types of placental cells (61). In human 
pregnancies, circulating IGF levels correlate proportionally with placental and 
fetal weights, where reduced levels due to nutrition can lead to fetal growth 
restriction (62). Both IGF-I and IGF-II are expressed in all cell types in the 
placenta as early as six weeks of gestation (63). IGF-II is important in facilitating 
the cytotrophoblast invasion of the maternal decidua early in human pregnancy 
and contributes to the placental vascularization, whereas, IGF-I is implicated with 
the placental development in the second trimester to term gestation (62). The 
exact IGF concentration in the immediate microenvironment of the chorionic villi 
during different gestational stages is not known, but the levels described are 
those measured in the umbilical cord blood. In a fully developed term placentae, 
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the IGF-I concentration is 71 – 132 ng/mL with IGF-II concentration being three-
fold higher at 246 – 356 ng/mL in the umbilical cord blood (Fig. 1.3) (64). 
Therefore, the effect of IGFs on PMSCs during different gestational stages may 
change depending on IGF ligand abundance and IGF-IR.  
 
1.4. Cellular Signaling and Mechanistic Regulation 
1.4.1. Low oxygen tension and hypoxic regulation 
Oxygen homeostasis is essential for the healthy physiology of an organism as 
well as to a single cell. Oxygen should be available in a narrow range to maintain 
the cellular health. The lower limit of this range is identified by the oxygen tension 
needed to maintain a reservoir of high-energy ATP molecules via aerobic 
respiration, which requires O2 for the electron transport chain (ETC) (65). On the 
other hand, the oxygen tension should not exceed a threshold (the top limit) in 
order to prevent the generation of reactive oxygen species (ROS) that have a 
destructive effect on the structure and function of macromolecules (65). In low 
oxygen tension, reduced cellular energy demand is met by glycolysis, which is 
adequate for maintaining stem cell pluripotency and generating iPSCs (66, 67). 
At low oxygen tensions (hypoxia), oxygen-sensing mechanism stabilizes the 
formation of the hypoxia inducible factor (HIF). Mainly, the HIF-1 system can 
compensate for the production of ATP, under hypoxic conditions, by increasing 
the transcription levels of several genes that control glycolysis, angiogenesis and 
erythropoiesis, and therefore, indirectly promotes cell survival (68). Formed 
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under hypoxic conditions, HIF-1 is a heterodimer complex of α- and β- subunits, 
where both are basic-helix-loop-helix (bHLH) proteins containing PAS (PER-
ARNT-SIM subfamily of bHLH) domains (69). At the protein level, the β-subunit 
(HIF-1β/ARNT) is continuously expressed and not degraded, while the α- subunit 
(HIF-1α) is regulated in the cytoplasm by regulatory proteins, such as prolyl 
hydroxylase domains -1, -2 and -3 proteins (PHDs), where PHD-2 utilizes 
molecular oxygen as a co-substrate and hydroxylates HIF-1α under normal 
oxygen tension oxygen (68, 70). Under low oxygen tension conditions, PHD-2 
cannot deliver hydroxyl groups on proline residues, and therefore, HIF-1α is 
stabilized by preventing the interaction with the von Hippel–Lindau protein and 
ubiquitin. Hence, HIF-1α is not targeted to the 26S proteasome for degradation 
(68, 70-72). At this stage, HIF-1 accumulates in the cytoplasm, translocates into 
the nucleus and dimerizes with HIF-1 to form the nuclear dimeric HIF-1 protein 
(Fig. 1.4B). HIF-1 can bind to the hypoxia responsive element (HRE) defined by 
the core sequence 5’-RCGTG-3’ (R = A or G), in promoters of target genes 
responsible for proliferation and survival (68, 71). At least seventy genes are 
regulated by HIF-1, encoding  cell surface receptors, extracellular matrix proteins 
and enzymes, angiogenic growth factors, cytoskeletal proteins, glucose 
transporters and glycolytic enzymes, proapototic factors, and other transcription 
factors (73). In addition, insulin and IGF-I share with hypoxia, the ability to 
activate transcription through the HRE, where HIF-1 is their main target to induce 
gene transcription (74). HIF-1α is stabilized by its direct phosphorylation by 
ERK1/2 and not by p38 MAPK or c-Jun N-terminal kinase (75). Therefore, 
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manipulating PMSC microenvironment with IGFs can change the stem cell fate 
by the induction of various hypoxia genes, which can be achieved directly by low 
oxygen tension or indirectly by HIF-1α phosphorylation. 
 
1.4.2. Insulin-like growth factor system  
1.4.2.1 Ligands and receptors 
Insulin-like growth factors (IGFs; IGF-I and -II) are polypeptides that stimulate the 
differentiation and self-renewal of many types of cells including stem cells (49), 
mainly through the interaction with the IGF-I receptor (IGF-IR). IGF-IR shares a 
structural homology domain with the insulin receptor (IR), which is expressed in 
two isoforms IR-A and IR-B, and can form hybrids (HR-A and HR-B) with the 
IGF-IR. IGF-II can also bind to its specific receptor, IGF-IIR, and with a higher 
affinity than IGF-I to the insulin receptor (IR). Both IGF-I and -II can bind to the 
hybrid receptor IGF-IR/IR with variable affinities (76). IR, IGF-IR and IR/IGF-IR 
hybrids are mitogenic RTKs, whereas IGF-IIR is not. IGF-II binding affinity to IR-
A is similar to insulin, however, it can activate the mitogenic signaling cascade, 
which is a different response than activation of IR (77). IGF-IR is more sensitive 
to IGF-I with a Kd of 1 nM, whereas, with a 10-fold lower affinity to IGF-II (78). 
Six IGF-binding proteins (IGFBPs, IGFBP-1 to -6) regulate the bioavailability of 
the IGF ligand in the extracellular vicinity of the receptors to sequester or release 
the IGFs, therefore, modifying the IGF actions (79). 
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Upon ligand binding, IGF-IR initiates mitogenic signals by activating the two main 
signal transduction pathways and effectors: the phosphoinositide 3-kinase 
(PI3K), AKT/PKB and the extracellular signal-regulated kinase (ERK1/2) (Fig. 
1.4A) (80). Through these molecules, IGF-IR can induce transcriptional activity 
that would promote survival, self-renewal and differentiation (81, 82). The 
downstream signal of IGF-IR is dependent on the differential phosphorylation 
pattern of its β-subunit and the resultant tyrosine residues available to bind 
adaptor molecules or kinase effectors such as, PI3K, AKT, RAS/RAF and 
ERK1/2 (83, 84). 
 
1.4.2.2. IGF-IR, adaptor molecules and signaling cascades  
IGF-IR is a transmembrane tetramer receptor that exists as heterodimers 
composed of two α and β hemireceptors linked by disulfide bonds in a β–α–α–β 
structure (Fig. 1.5) (85). IGF-IR has three properties related to cell growth, where 
it (i) promotes survival and protects from apoptosis both in vivo and in vitro, (ii) 
stimulates cell-growth, and (iii) is required for the establishment and maintenance 
of a tumor-like phenotype (83). 
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Upon activation of the extracellular α subunits of the IGF-IR, autophosphorylation 
of tyrosine residues (Y1131, 1135, 1136) on the β-subunits creates high affinity 
binding sites for signaling adaptor molecules and substrates. SHC and the insulin 
receptor substrate-1 (IRS-1) are two adaptor/substrate molecules interact with 
Tyr-950 at the NPXY motif of the β subunit of IGF-IR (Fig. 1.5) (83, 86). For the 
ERK1/2 signaling pathway, SHC interacts directly with the IGF-IRβ (at Tyr-950) 
which gets phosphorylated at tyrosine residues (Tyr-317 and/or Tyr-239/240) to 
recruit the SH2 domain binding of GRB2. In turn, GRB2 interacts via its SH3 
domain with SOS that subsequently activates c-RAS by exchanging GTP for 
GDP leading to the sequential phosphorylation of RAF, MEK1/2 and then 
ERK1/2 (Fig. 1.4) (86-91). To activate the PI3K/AKT signaling, p85, the 
regulatory subunit of PI3K, interacts directly with IGF-IRβ at YAHM motif at Tyr-
1316 independent of Tyr-950 — the site for IRS-1 and SHC binding (Fig. 1.5) 
(92). The C-terminal c-SH2-domain of p85 is responsible for binding with the 
carboxy-terminal of IGF-IRβ, while both n/c-SH2 domains of p85 bind to the IR 
corresponding C-terminal motif (YTHM at Tyr-1322) causing a more efficient and 
stronger interaction between IR and p85 than that with IGF-IR (92, 93). 
Therefore, the difference between the binding of p85 to either of IGF-IR and IR 
would exert different biological responses due to the dose of IGF-I or -II that can 
activate both IGF-IR and IR. However, IR has a 100-fold lower affinity to IGF-I 
than that for insulin to exert an effect (58). Besides the direct interaction with the  
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Figure 1.5. IGF-IR binding domains. IGF-IR is a class-2 transmembrane receptor 
tyrosine kinase with two extracellular α-subunits and two β-subunits that extends 
intracellularly spanning the membrane. The α-subunits contain the ligand binding 
domain, while the β-subunits contain the kinase function for autophosphorylation 
and binding to various adaptors.  
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IGF-IRβ, the ERK1/2 and the PI3K/AKT signaling is activated by the indirect 
interaction via IRS-1 recruited to IGF-IRβ. IRS-1 is a main adaptor of the IGF-IR 
implicated with the mitogenic effect of IGF-IR, inhibition of apoptosis and 
transformation of cells into the tumoral cells when over-expressed, whereas, its 
downregulation has been associated with the inhibition of differentiation and the 
induction of apoptosis (80, 94). It has been shown that the N-terminal domain of 
IRS-1 binds to the p-IGF-IRβ to induce over 20 potential phosphorylated sites 
available to recruit GRB2, NCK, the p85 regulatory subunit of PI3K, the tyrosine 
phosphatase SH-PTP2, SRC-like kinase FYN and the Ca2+-ATPases SERCA1 
and AERCA2 (86, 95). The phosphorylation of IRS-1 at Tyr-895 recruits GRB2 
and transduces the signal through the ERK1/2 (87), whereas, the 
phosphorylation of Tyr-612/-632 would activate the PI3K signaling by recruiting 
p85 binding (96). Therefore, both ERK1/2 and PI3K/AKT signaling pathways are 
also activated by IGF-IR via the indirect binding of GRB2 and p85, respectively, 
to the IRS-1 (86, 87, 91), and therefore, a wider range of interacting adaptors can 
be mediated to define the signaling cascade. In the stem cell niche, the 
microenvironmental components (oxygen tension and IGFs) define the signaling 
cascades in stem cells to promote either self-renewal or differentiation depending 
on receptor activation and the combination of signaling cascade. 
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1.5. Stem Cell Differentiation and Fate Specification 
1.5.1. Stem cell differentiation conditions 
Two approaches are undertaken to induce stem cell differentiation using either 
intrinsic nuclear reprogramming, via transcription-factor-mediated 
reprogramming, or extrinsic, via growth-factor-mediated stimulation (97). Similar 
to iPSC generation, intrinsic nuclear reprogramming has been successful but is 
still limited to acquire only few lineages, such as cardiomyocytes, hepatocytes, 
and neurons due to the limitation of known reprogramming factors (97). For this 
purpose, reprogramming and de-differentiation to an iPSC is required. However, 
to cover a wider range of differentiation lineages, extrinsic growth factor 
stimulation is the solution to acquire cells from all three germ layers. In vivo, the 
natural route of stem cell differentiation is mediated via extrinsic growth factor 
signaling within the microenvironment. In their niche, ESCs are in quiescent 
dormant state that is maintained by three interactions with the niche components: 
the supportive cellular contact, the ECM, and the paracrine growth factor 
signaling (51). Thus, manipulating any of these conditions will disturb the natural 
niche of the stem cell causing asymmetrical division towards a differentiated 
phenotype. In vitro, differentiation is triggered by withdrawing maintenance 
growth factors or stimulating by differentiation promoting growth factors and 
molecules (98, 99). As shown in Fig. 1.6, differentiation of adult MSCs follow 
specific differentiation protocols using varying combinations of growth factors and 
chemical compounds, such as butylated hydroxyanisole and NGF for neuronal 
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differentiation; BMP-12 for tendocyte differentiation; dexamethasone, 3-isobutyl-
1-methylxanthine, insulin and indomethacin for adipogenic differentiation; 
monothioglycerol, HGF, oncostatin, dexamethasone, FGF4, insulin, transferrin 
and selenium for hepatocytic differentiation; b-FGF and VEGF for endothelial 
differentiation; TGF-β1, insulin, transferrin, dexamethasone, ascorbic acid for 
chondrogenic differentiation; insulin, transferrin and selenium for skeletal 
myogenic differentiation; dexamethasone, ascorbic acid and β-glycerophosphate 
for osteogenic differentiation (Fig. 1.6) (100-105). Therefore, from a common 
MSC population in the mesoderm, receiving different extrinsic stimuli can initiate 
differentiation towards specific cell type by triggering a tissue specific 
transcription factor, as SOX5/6/9 for chondrocytes, PPARγ for adipocytes, MyoD 
family for myoblasts, and RUNX2/Osterix for osteoblasts (106).  
 
1.5.2. Osteogenic differentiation 
Bone tissue is a calcified connective tissue derived from the mesodermal lineage 
of the developing embryo. Osteoblasts, the mononucleated bone forming cells, 
are of a mesenchymal origin responsible for synthesis and mineralization of bone 
tissue initially at the forming stage and later at remodeling of the skeletal bone 
structure (107). During in vitro osteogenic differentiation, MSCs follow the 
intramembranous ossification mode starting by condensation of the stem cell 
27 
 
 
  
 
Figure 1.6.  MSCs are multipotent in vitro and differentiate towards all three 
germ layer lineages. Mesenchymal stem cells including PMSCs are able to self-
renew and differentiate towards all three germ layer lineages of ectoderm, 
mesoderm and endoderm. Transdifferentiation of MSCs in vivo is still 
controversial, but it has been achieved in vitro with different stimulation factor 
combinations which may not be present in the natural MSC niche in vivo.  
Reproduced from Nature Reviews Immunology 8(9), Uccelli A, Moretta L and 
Pistoia V. Mesenchymal stem cells in health and disease. Page 727 Copyright 
2008, with permission from Nature Publishing Group. 
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population and direct differentiation into osteoblasts, without the need of 
cartilaginous template for ossification (108). Osteogenic differentiation has three 
phases: proliferation and condensation, extracellular matrix secretion and 
maturation, and matrix mineralization (109). The initiation of osteoblast formation 
is controlled by RUNX2, a lineage-specific transcription factor responsible for 
directing the multipotent MSC towards the osteoblast lineage (110). RUNX2 
expression is essential for MSC proliferation and condensation with the highest 
expression just prior to differentiation; RUNX2 can inhibit differentiation if its level 
remains high (110-112). The lack of RUNX2 in mice causes bone malformation 
due to the absence of osteoblasts and death shortly after birth due to breathing 
dysfunction; also the lack of RUNX2 is manifested in human disease known as 
cleidocranial dysplasia (110, 112). Another known lineage-determining factor, 
Osterix, is downstream of RUNX2 and is also required for complete commitment 
of progenitor cells towards the osteoblast differentiation (113). At the early stage 
of osteoblast differentiation, RUNX2 is responsible for transcriptional 
upregulation of matrix deposition proteins (type I collagen, osteopontin, bone 
sialoprotein and osteocalcin), but is not essential to maintain these proteins in 
mature osteoblasts (107, 110, 112). During osteoblast maturation, higher 
expression of both RUNX2 and osteopontin higher expression is a marker of 
immature osteoblasts, whereas the upregulation of osteocalcin marks mature 
osteoblast with a loss of RUNX2 and osteopontin expression (114).  
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1.5.3. Role of low oxygen tension and IGFs in osteogenic differentiation 
In a low oxygen tension microenvironment, osteogenic differentiation is severely 
inhibited with reduced matrix maturation and mineralization starting at an early 
stage, thereby keeping the cells in a stem cell like state (115). This inhibition is 
mediated by HIF-1α, under low oxygen tension or if stabilized in room air, to 
reduce RUNX2 expression and alkaline phosphatase activity and delay matrix 
production and mineralization (115, 116). However, stem cell preconditioning in 
low oxygen tension has shown an improved state of osteogenic differentiation. In 
their natural microenvironment, undifferentiated stem cells are in a steady 
dormant state with a low energy demand that is mostly dependent on glycolysis, 
with very low aerobic respiration and mitochondria count, even in room air 
conditions (117). On the other hand, osteogenic differentiation goes through 
several high energy demanding processes including matrix production, 
maturation and mineralization (115). Indeed, differentiating osteoblasts undergo 
a metabolic switch from anaerobic glycolysis to aerobic mitochondrial respiration 
that is inhibited under low oxygen tension (116). Generally, a metabolic switch is 
achieved by decreasing glycolysis enzymes and lactic acid production, 
upregulation of mitochondrial biogenesis and ATP production, and upregulation 
of antioxidant enzymes to eliminate reactive oxygen species (118, 119). By 
mathematical modeling, an oxygen gradient exists in the bone marrow where the 
most primitive stem cells are located in a very low oxygen tension 
microenvironment far from a bone marrow sinus (120), which suggests that 
differentiating MSCs move towards higher oxygen tension upon osteoblast 
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differentiation. Therefore, low oxygen tension can maintain stem cells in a higher 
multipotent proliferative state and inhibit differentiation via hypoxic molecular 
signaling and low energy supply that does not support the metabolic demand for 
a mature differentiated state. 
 
In vitro, osteogenic differentiation is triggered by the combined signaling of 100 
nM dexamethasone, 50 µM ascorbic acid followed by 10 mM β-glycerophosphate 
in presence of 10% fetal bovine serum (121). However, optimization experiments 
using lower concentration of dexamethasone (5-10 nM) and a higher 
concentration of ascorbic acid (150-250 µM) achieved a higher level of 
osteogenic differentiation that was significantly improved in presence of human 
serum or a defined xeno-free media — supplemented with specific growth factors 
such as insulin, FGF and activin A (121). Therefore, optimization of differentiation 
conditions can be achieved by changing the growth factor composition in the 
microenvironment. In immediate contact with bone cells in vivo, several growth 
factors, hormones and cytokines (BMPs, sonic hedgehog proteins, Wnt/β-
catenin, FGF and IGF) mediate osteoblast commitment, growth and 
differentiation (107). IGFs (IGF-I and IGF-II) secreted by skeletal bone cells play 
an important role in paracrine/autocrine stimulation of bone formation, growth, 
and metabolism (122, 123). In osteoblast primary cultures, one of IGF-I functions 
is to exert an anti-apoptotic action and promote survival of differentiating 
osteoblasts especially at later stages (123). Also, IGF-I was shown to play a 
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chemotactic role that stimulates the recruitment and migration of osteoblasts 
(124). Local overexpression of IGF-I in osteoblasts is shown to accelerate the 
rate of bone formation and increase the pace for matrix mineralization (125). The 
function of IGF-I signaling is mediated via the IGF-IR, which upon its deletion 
caused a failure to mineralize bone matrix (125). In disease conditions such as 
osteoporosis, primary osteoblast cultures has an impaired IGF-IR signaling 
decoupled from IGF-I stimulation, which possibly causes lower proliferation rate 
and differentiation and therefore bone loss (126). Therefore, IGF has no effect on 
osteoblast commitment (no change in RUNX2 expression), but enhances cell 
maturation at later stages for matrix secretion (increased type-I collagen) and 
mineralization (127).  
 
1.6. Scope of Thesis 
1.6.1. Tissue regenerative therapy – stem cell promise 
In the twenty first century, the burden of organ failure and degenerative diseases, 
which cannot be corrected by drugs alone, has been focused on the promise in 
cell replacement therapy and tissue regeneration (128). Some of the diseases 
that are targeted by stem cell therapy include hormonal dysfunction (diabetes 
and growth hormone), neurodegenerative diseases (Parkinson’s, Alzheimer’s 
and Huntington’s) and cardiovascular diseases (myocardial infarction, peripheral 
vascular ischemia) as well as various injuries in the cornea, skeletal muscle, skin, 
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joints and bones (129). In this context, stem cells have a great potential for 
tissue/organ repair, replacement of dying cells and promoting the survival of 
damaged tissue (130). However, the specific use of stem cells from the sources 
available has their own risks and limitations that can restrict their use for tissue 
regeneration. ESCs, in principle, can be used to generate any cell type from the 
three germ layers; however, the uncertain result of tumorigenicity potential and 
the ethical and political controversies converge to an obstacle for successful use 
(128). To date, one clinical trial is ongoing to test the use of ESC in spinal cord 
injury (131). In line with pluripotent ESCs, iPSCs have the advantage of being 
generated from autologous sources that can eliminate graft versus host disease; 
however, they are not ready for clinical trials due to the lack of understanding of 
the optimal reprogramming effect on cells behavior in vitro and optimally for in 
vivo application. MSCs so far, show great promise as they have less ethical 
controversies and less tumorigenicity (do not form teratomas in vivo) due to less 
proliferative potential and a more restricted lineage differentiation. Also, MSCs 
have the immunomodulatory effect to reduce an immune response and were able 
to engraft successfully in a therapy resistant graft versus host disease patients 
(130). Among the adult MSC populations described to date, only the 
hematopoietic stem cells, isolated from bone marrow and umbilical cord blood, 
have been used in over 1,200 active open trials (128, 132). More trials are testing 
other sources of stem cells for clinical intervention, with 3 embryonic-, 36 
adipose-, 280 neural- stem cells and 115 using MSCs (128). In Canada, there 
are 204 open or pending clinical trials using stem cells, as listed on the NIH 
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website clinicaltrials.gov (128). Therefore, research is still ongoing to optimize the 
use of MSCs from alternative sources for tissue regeneration therapies.  
 
1.6.2. Hypothesis and objectives 
In this study, we aim to obtain a homogeneous multipotent stem cell population 
from different gestations of the human placenta (PMSCs), optimize cell culture 
conditions and manipulate the stem cell fate to induce cell differentiation in vitro. 
By manipulating the stem cell microenvironment, my objective is to characterize 
the role of IGF-I and -II, abundant growth factors in the placenta, to regulate 
PMSC fate under physiological low oxygen tension by investigating, i) the 
signaling pathways that promote stem cell multipotency and proliferation and ii) 
the differentiation commitment of PMSCs towards osteogenic progenitor cells. 
 
The central hypothesis is that the interactive signaling between IGFs and oxygen 
tension is required to alter gestational stage dependent PMSC fate towards self-
renewal or differentiation. 
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The effect of low oxygen tension on IGF signaling in PMSC is investigated as 
follows: 
1. To characterize the role of IGF-I on early and late gestation PMSCs 
multipotency and proliferation and the signaling cascade governed by 
ERK/2 and the AKT signaling pathways in low oxygen tension conditions 
(Chapter 2). 
2. To compare and contrast the role of IGF-I and IGF-II in maintaining PMSC 
multipotency, proliferation and signaling in low oxygen tension conditions 
(Chapter 3). 
3. To determine the role of IGFs on PMSC commitment and differentiation 
towards the mesodermal osteogenic lineage (Chapter 4). 
In this study, we showed that the placenta is an abundant source of multipotent 
mesenchymal stem cells and that the physiological microenvironment is crucial 
for directing the stem cell fate to maintain multipotency or differentiation. This 
work is an antecedent investigation in understanding the niche conditions 
required to determine the specific fate of stem cells that will lead to improved 
success in tissue regenerative therapies. 
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CHAPTER TWO 
Low Oxygen Tension and Insulin-like Growth Factor-I (IGF-I) Promote 
Proliferation and Multipotency of Placental Mesenchymal Stem Cells 
(PMSCs) from Different Gestations via Distinct Signaling Pathways 
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2.1. INTRODUCTION 
 
Human placenta is a readily available source of adult stem cells, termed 
placental mesenchymal stem cells (PMSCs) that originate from the primitive 
allantoic mesenchyme derived from the embryoblast (1). Stem cells have been 
isolated from different parts of the placenta (chorionic villi, membranes, umbilical 
cord, chorioallantois and amniotic fluid) and the largest source is the chorionic 
villi (2, 3). Studies have shown that PMSCs are multipotent, can differentiate into 
cells of all three germ layers including cartilage, bone, endothelial, adipose, 
muscle or neuronal lineages, express embryonic stem cell markers such as 
OCT4, SSEA-4, TRA-1-61, TRA-1-80, and are devoid of trophoblastic and 
hematopoietic markers (4-7). PMSCs are potential candidates for regenerative 
therapy and tissue engineering, as they have significantly less or no allo- or 
xenogeneic immune response, and suppress alloreactive T cells in a mixed 
lymphocyte reaction (8, 9).  
 
The stem cell microenvironment or niche maintains normal pluripotent capacity 
and enables cells to respond appropriately to cues when regeneration is needed. 
Abnormalities in this capacity can lead to disease states such as tumorigenesis 
or an opposite outcome, poor healing. During normal human pregnancy, the 
microenvironment of the developing placenta undergoes changes in oxygen 
tension and growth factor concentrations. IGF-I concentration is low at early 
gestation and increases at term to reach ~100 ng/mL in the umbilical cord 
venous blood (10). Similarly, oxygen tension is very low at implantation, near 0%, 
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reaches 2.4% O2 at first trimester and increases gradually after the formation of 
the utero-placental circulation to reach ~5 - 8% O2 similar to adjacent 
endometrium (11, 12). Hence, PMSCs isolated from early and late gestational 
stages may have different responses to IGF-I and low oxygen tension mimicking 
their natural microenvironment. 
 
Insulin-like growth factors (IGFs; IGF-I and -II) are major autocrine/paracrine 
growth factors that regulate growth and differentiation during development of all 
tissues including placenta, and they are expressed as early as in preimplantation 
embryos in humans (13, 14). Circulating levels of IGF-I and -II correlate with 
placental and fetal weights, where both can regulate cell growth, differentiation 
and cell-fate changes through several mitogen activation cascades mainly 
through the IGF-I receptor (IGF-IR), a receptor tyrosine-kinase (15-17). Upon 
ligand binding, IGF-IR initiates mitogenic and metabolic signals by activating the 
two main signaling transduction pathways: the phosphoinositide 3-kinase (PI3-
K)/AKT/PKB and the extracellular signal-regulated kinase (ERK1/2) (18, 19). In 
certain niche conditions, these molecules can induce transcriptional activity that 
would promote growth, differentiation, survival or self-renewal (20, 21). However, 
little is known about signaling mechanisms underlying IGF-I actions on MSC 
proliferation and fate changes. 
 
Oxygen tension plays a major role in stem cell proliferation and differentiation, 
especially in the placenta. It was shown that cytotrophoblasts proliferate in low 
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oxygen tension (2% O2), while they differentiate in high oxygen tension (20% O2) 
(11). Also, low oxygen tension can retard the differentiation process of 
mesenchymal/progenitor stem cells into adipose and cartilage forming cells 
through changes in hypoxia inducible factor-1 (HIF-1) signaling (22-24). Under 
low oxygen tension, HIF-1α, the oxygen-sensitive α-monomer of the HIF-1, is 
stabilized and prevented from ubiquitination and proteosomal degradation (25, 
26). HIF-1 can induce transcription of at least 70 genes containing functional 
hypoxia responsive element (HRE). However, it has been estimated that more 
than 200 genes and up to 5% of the human genes, depending on the cell-type, 
are induced by hypoxia, via HIF-1, but not necessarily all are regulated through 
HRE regions (27-29). HIF-1 can target major genes of diverse functions including 
cell surface receptors, angiogenic growth factors, glucose transporters, and 
glycolytic enzymes that primarily promote cell survival (25, 30). Interestingly, 
downstream of IGF-I signaling, p-ERK1/2 phosphorylates HIF-1α to increase its 
stability under room air by inhibiting its proteosomal degradation, thereby 
inducing transcription from HRE containing promoters (31, 32). Low oxygen 
tension is required to maintain stem cell pluripotency by HIF-2 interaction with the 
OCT4 promoter region to induce increased transcriptional activity (33). OCT4 is 
the master regulator of pluripotency in ESCs and is indispensible to generate 
iPSCs, and is lost upon differentiation (34-38).  
 
To determine the developmental changes and signaling differences in the 
presence of IGF-I and low oxygen tension, we used both Preterm (P-) and Term 
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(T-) PMSCs to assess their role in determining stem cell proliferation and 
multipotency. We show here that the pattern of the IGF-IR, IRS-1, ERK1/2 and 
AKT levels and phosphorylation are gestational stage-dependent and are 
modulated by low oxygen tension. We conclude that IGF-I signaling is dependent 
on oxygen tension, and that the balance between the two factors regulates OCT4 
levels, which is a marker for stem cell pluripotency.  
 
2.2. MATERIAL AND METHODS 
2.2.1. PMSC Isolation and Characterization 
PMSCs were isolated from human placentae of two gestational ages, Preterm 
PMSCs from 10-13 weeks and Term PMSCs from 37-42 weeks (at least three 
PMSC primary cell populations from each gestational age). After informed 
consent, preterm placentae were collected from patients who underwent 
therapeutic pregnancy termination, and term placentae from healthy pregnant 
women who underwent elective Cesarean section. Immediately after surgery, 
small pieces of chorionic villi were dissected free of maternal decidua. Tissue 
samples were minced mechanically and enzymatically digested with collagenase 
IV/hyaluronidase and DNase I, followed by trypsin/EDTA for 20 min at 37ºC, 
followed by 10 min wash at 4ºC in 10% fetal bovine serum (FBS) in PBS (Gibco, 
Mississauga, ON). Cells were passed through a nylon tissue mesh (45 μm) to 
obtain a single cell suspension. Next, cells were separated on a Percoll (Sigma) 
discontinuous gradient (layers 4 and 5) modified from Worton et al. for 
hematopoietic stem cell isolation (39), and then seeded in tissue culture flask 
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(Falcon) using DMEM/F12 media (Gibco, Mississauga, ON) containing 10% FBS 
and antibiotic-antimycotic solution. After 4 days, media was changed and non-
adherent cells were washed to leave behind adherent PMSCs able to form 
colonies.  
 
Placental MSCs were characterized as mentioned previously (40-42), by flow 
cytometry for the absence of hematopoietic markers CD45 and CD34, and for 
cytokeratins (-8, -9, and -17), and the presence of MSC markers CD105 (SH2) 
and CD73 (SH3, SH4), and CD117 (c-Kit, stem cell factor receptor). In short, cell 
monolayer was trypsinzied by 1X TrypLE Express (Gibco, Mississauga, ON) for 5 
min and centrifuged at 1000 rpm. Cell pellet was resuspended in 1x DPBS 
(Gibco, Mississauga, ON) and incubated with the primary Ab for 1-hr at 37° C, 
followed by Alexafluor 488 secondary Ab (A11029, Invitrogen) for 30 min at 37° 
C. Cells were then washed and resuspended in 1 mL of 1x DPBS and run using 
Beckman Coulter flow-cytometer reaching 10,000 counts.  
By immunoblotting, PMSCs were positive for pluripotency markers OCT4, SOX2 
and NANOG. Also, PMSCs were able to differentiate towards osteogenic, 
endothelial, adipose and muscle lineages from mesodermal lineage and neuron-
like cells expressing Nestin from the ectodermal lineage.  
 
2.2.2. Cell Culture and Incubation in Low Oxygen Tension 
 For each experiment, two preterm or term PMSC populations were used in 
triplicate. Cells were cultured and maintained using DMEM/F12 media with 10% 
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FBS and FGF-2 (100 ng/mL) (Gibco, Mississauga, ON). Before treatment, cells 
were cultured in DMEM/F12 with 10% FBS for 24-hrs. Upon treatment, PMSCs 
were switched directly to fresh serum free media containing IGF-I (0 – 100 
ng/mL) in the presence or absence of either 5 μM U0126 or 10 μM LY294002 
(Cell Signaling Tech., Danvers, MA). Proliferation was measured using the WST1 
reagent assay (Roche) following manufacturer’s protocol. PMSCs were seeded 
at 5,000 cells/100 µL in 96-well plates. All cell cultures were then placed in either 
a 5% CO2 incubator or a hypoxia chamber—filled with a 1% O2, 5% CO2, 
balanced N2 gas mixture (BOC Canada Ltd, Toronto, ON) for 15 min to ensure 
saturation.  The saturation of the oxygen in the chamber was measured using a 
Hudson 5590 Oxygen Monitor (Hudson, Ventronics Division). Thereafter, the 
chamber was placed in a tissue-culture incubator at 37o C. At the end of the 
experiment, oxygen tension in culture media was measured using the ABL700 
series blood gas analyzer (Radiometer, Copenhagen, Denmark).  
 
2.2.3. Human Phospho-kinase Array  
To screen for kinases phosphorylated upon IGF-I stimulation under room air or 
low oxygen tension, PMSCs were serum-deprived for 24-hrs under 20% or 1% 
oxygen. For IGF-I treatment, PMSCs from both oxygen tension conditions were 
washed with 1x PBS (x 3) and then stimulated with 100 ng/mL of IGF-I for 15 
min., a proteome ProfilerTM Array (#ARY003, R&D system, Minneapolis, MN) 
Part A was used according to manufacturer’s protocol. Treated cells were rinsed 
with PBS and then solubilized in lysis buffer and the protein concentration was 
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determined by Bradford Assay (BioRad laboratories, Hercules, CA). Kinase array 
was incubated with cell lysate of the same protein concentration, washed, and 
specific kinases phosphorylated were identified by detection biotinylated antibody 
cocktail A. Immunocomplexes were detected with a streptavidin-HRP binding and 
the signal was developed using enhanced chemiluminescence (ECL) according 
to the manufacturer’s instructions (Perkin Elmer Life Sciences), and documented 
on Kodak Biomax film (Rochester, NY, USA).   
 
 
2.2.4. Immunoblotting 
 Cell lysates were prepared using 1x cell lysis buffer for phospho-proteins 
according to manufacturer protocol (#9803, Cell Signaling Technologies, 
Burlington, ON, CAN). Protein samples (10-20 μg) were resolved by SDS-PAGE, 
and then transferred onto PVDF membranes (Millipore, Bedford, MA). The 
membranes were blocked with 5% non-fat-dry milk in 1x TBS (Tris-buffered 
saline) for 1 hr at room temperature. Blots were then washed in 1x TBS 0.1% 
Tween 20 (TBS-T) (3x for 5 min) followed by incubation at 4oC overnight with 
primary antibodies as per manufacturers’ protocols. Blots were then washed 
using TBS-T (3x for 10 min) and were incubated with secondary HRP-labelled 
antibody for 1 hr at RT. Immunocomplexes were detected by ECL and detected 
using VersaDOCTM Imaging System (Bio-Rad). 
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2.2.5. Antibodies 
For flow cytometry, the following antibodies were used: CD-73 (#550256) (BD 
Pharmingen, San Jose, CA), PE conjugated CD105 (#12-1057-73) (eBioscience, 
San Diego, CA) CD-117/c-Kit (sc-13508) (Santa Cruz Biotech., Santa Cruz, CA). 
To detect the IGF-I activated signaling molecules, the following antibodies were 
used: phospho-p44/42 MAPK (#4377), p44/42 MAPK (#9102) phospho-AKT 
(Ser473, #4051), AKT (#9272), PCNA (PC10, #2586), and IRS-1 (#2382) from 
Cell Signaling Technologies (Danvers, MA, USA). For OCT3/4, antibody (N-19, 
sc-8628) (Santa Cruz Biotech., Santa Cruz, CA, USA) was used. For the 
detection of hypoxia markers, HIF-1 alpha antibody (H206, sc-10790) (Santa 
Cruz Biotech., Santa Cruz, CA, USA) was used. For loading control, pan-Actin 
Ab-5 (#MS-1295) (Thermo Fisher Scientific, Fremont, CA) was used. The 
secondary antibodies used for immunoblotting were goat anti-rabbit (#170-6515) 
or anti-mouse (#170-6516) HRP conjugated antibodies (BioRad laboratories, 
Hercules, CA) or donkey anti-goat antibody (sc-2020) Santa Cruz Biotech., Santa 
Cruz, CA, USA).  
 
2.2.6. Statistical Analysis 
All experiments were run in triplicates from three independent experiments each; 
whenever possible, three or more PMSC primary lines were used from each 
gestational stage. All graphs and analyses were generated using GraphPad 
Prism Software 5.0 (GraphPad Software, San Diego, CA). A Two-way ANOVA 
with Bonferroni post hoc test was used for the PMSC WST1 proliferation assay 
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and densitometry quantifications. Data are expressed as mean ± standard error 
of the mean (SEM); values were considered significant when p<0.05. 
 
2.3. RESULTS 
2.3.1. IGF-I mediated PMSC proliferation response is dependent on oxygen 
tension and gestational age 
 In PMSC cultures, low oxygen tension (1% O2) achieved 52.2 mmHg oxygen 
tension in the culture media. This oxygen tension is physiological during human 
pregnancy at 12-13 weeks (early second trimester), which ranges between 46.5 
mm Hg at the endometrium (maternal side) to 60.7 mm Hg in the placenta (fetal 
side) (12). This low oxygen tension stabilized HIF-1α confirming the hypoxic 
condition (Fig. 2.1A) and increased OCT4 levels in both types of PMSCs 
confirming enhanced multipotency (Fig. 2.1B). Low oxygen tension had no effect 
on the expression of surface markers (CD73, CD105 and CD117/c-kit) in both P- 
and T-PMSCs (Fig. 2.1C). However, gestational age differences were detectable 
between the two PMSCs, higher abundance of OCT4 in room air (one-way 
ANOVA, p<0.05) and higher CD117/c-kit expression (~15-fold) in P-PMSCs than 
in T-PMSCs.  
To demonstrate the effect of IGF-I on PMSC proliferation, we subjected P- and T-
PMSCs to increasing concentrations of IGF-I and low oxygen tension. P-PMSCs 
exhibited continued proliferation in serum-free media, which was increased in a 
dose-dependent manner by addition of IGF-I (plateau at 50 ng/mL) (Fig. 2.2A).  
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FIGURE 2.1. Low oxygen tension increases OCT4 levels in PMSCs and 
maintaining stemness.  (A) HIF-1α levels in P-PMSCs in10% fetal bovine 
serum (FBS) in room air or low oxygen tension at 48 hrs (T-PMSCs show similar 
levels). The positive control is PMSCs in 10% FBS treated with 0.1 mM cobalt 
chloride in room air. β-Actin levels indicate equivalent protein loading.  (B) OCT4 
levels in P- and T-PMSCs in 10% FBS cultured in room air or low oxygen tension 
for 48 hrs. β-Actin levels indicate equivalent protein loading. (C) Stem cell 
surface markers (CD73, CD105, CD117) of P- and T-PMSCs in 10% FBS in 
room air or low oxygen tension expressed as % of total positive cells (measured 
in 10,000 cells, n=3; one-way ANOVA, p<0.05, * = significant difference between 
low oxygen and room air). Low oxygen tension increased OCT4 levels in preterm 
and term PMSCs. Stem cell surface marker expression was not changed by low 
oxygen tension in preterm or term PMSCs.  
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However, low oxygen tension together with IGF-I (100 ng/mL) further increased 
P-PMSC proliferation (Fig. 2.2A). On the other hand, T-PMSCs had not 
significantly increased proliferation in response to IGF-I in room air that was 
further increased by low oxygen tension (highest at 10 ng/mL and decreased at 
higher concentrations) (Fig. 2.2B). Since the proliferation of P-PMSCs and T-
PMSCs in low oxygen tension was noticeably different at 100 ng/mL of IGF-I, a 
time course experiment (over 12, 24 and 48-hrs) was conducted. In room air, 
PMSC proliferation was significantly increased by IGF-I in both P- and T-PMSCs 
after 24-hrs (3.5-fold and 2.5-fold, respectively) (t-test, P = 0.0005) (Fig. 2.2C and 
D). Low oxygen tension enhanced the IGF-I stimulated proliferation of both 
PMSCs (up to 4.6-fold in P-PMSCs compared with 3.1-fold in T-PMSCs) (t-test, 
P = 0.0001). However, at 48-hrs, the proliferation subsided in both P-PMSCs and 
T-PMSCs to ~ 0.5-fold in both oxygen tensions (Fig. 2.2C and D). Overall, the 
response to IGF-I was gestational age-dependent and enhanced by low oxygen 
tension—P-PMSCs having a higher proliferation response.  
  
2.3.2. IGF-I mediated PMSC OCT4 expression is dependent on oxygen 
tension and gestational age 
Similar to the proliferation response, we checked for multipotency regulation by 
IGF-I concentration and exposure time in low oxygen tension. In P-PMSCs, IGF-I 
(100 ng/mL) increased OCT4 levels, in both oxygen tension conditions (Fig. 
2.3A), whereas in T-PMSCs, OCT4 only increased in response to IGF-I in room 
air (Fig. 2.3B). OCT4 was also temporally regulated; in P-PMSCs 
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FIGURE 2.2. Low oxygen tension increased PMSC proliferation in response 
to IGF-I. PMSC proliferation was assessed using the WST-1 colorimetric 
proliferation assay using absorbance at 450 nm with a background reference of 
650 nm. (A) P-PMSCs and (B) T-PMSCs were treated with increasing 
concentration of IGF-I concentrations (0, 10, 50 and 100 ng/mL) in room air or 
low oxygen tension for 48-hrs. (C) P-PMSCs and (D) T-PMSCs were treated with 
IGF-I (100 ng/mL) under room air or low oxygen tension in a time course from 0 
to 48-hrs. Two-Way ANOVA, P<0.05, n=8; a = significant difference between 
room air and low oxygen tension, * = significant difference by different IGF-I 
concentration. A cell counting experiment has been done as shown in Figure 
S2.1A and B. In both P- and T-PMSCs, low oxygen tension enhanced the effect 
of IGF-I on cellular proliferation.  
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under room air, IGF-I gradually increased OCT4 levels that peaked at 12-hrs, 
and was stable up to 48-hrs (Fig. 2.3C). Low oxygen tension induced a similar 
expression pattern with a maximal increase at 24-hrs. In T-PMSCs, OCT4 
expression increased rapidly after IGF-I exposure in room air, but not in low 
oxygen tension (Fig. 2.3D). The maximal increase in OCT4 expression (up to 
1.5-fold) occurred earlier in T-PMSCs (6-hrs) compared with P-PMSCs (12 hrs) 
suggesting that IGF-I effect is gestational age-dependent—increased sensitivity 
in T-PMSCs. 
 
2.3.3. ERK1/2 and AKT signaling downstream of IGF-IR 
To map the downstream effectors of IGF-I signaling, we used a phospho-kinase 
array (Fig. 2.4A). Short-term exposure of P-PMSCs (15 min) in room air to IGF-I 
increased phosphorylation of ERK1/2 (spots A5, A6) (Fig. 2.4B). Increased p-
ERK1/2 by low oxygen tension was not increased further by IGF-I (Fig. 2.4B). 
AKT phosphorylation (spots B9, B10) was increased by IGF-I in both room air 
and low oxygen tension conditions (Fig. 2.4B). Similarly, IGF-I increased p-
ERK1/2 in room air, and low oxygen tension increased the phosphorylation 
independent of IGF-I (Fig. 2.4C and D). In addition, p-AKT was dependent on 
IGF-I for phosphorylation and was less so by low oxygen tension (Fig. 2.4C and 
D). The change in signaling proteins was not associated with changes in IGF-IR 
or in OCT4 levels (Fig. 2.4C). Overall, IGF-I increased ERK1/2 phosphorylation 
under room air and less under low oxygen tension, which was already induced  
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FIGURE 2.3. OCT4 levels in PMSCs in response to IGF-I and low oxygen 
tension. Levels of OCT4 were quantified by densitometry of immunoblots in P-
PMSCs and T-PMSCs. (A) P- and (B) T-PMSCs were stimulated with increasing 
concentration (0, 10, 50 and 100 ng/mL) of IGF-I for 48-hrs under room air or low 
oxygen tension. Also, (C) P- and (D) T-PMSCs were stimulated over time with 
100 ng/mL over 48-hrs. Quantification by densitometry was normalized to β-Actin 
for protein load and DNA content to account for stem cell heterogeneity. Two-
Way ANOVA, P<0.001, n=3, a = significant difference between room air and low 
oxygen tension; * = significant difference by different concentration of IGF-I or 
stimulation time. IGF-I increased OCT4 levels in both P- and T-PMSCs. OCT4 
levels increased slowly over 48-hrs in both P- and T-PMSCs.  
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independent of IGF-I; however, IGF-I was required for AKT phosphorylation 
under both oxygen tensions. 
 
2.3.4. Phosphorylation of AKT and ERK1/2 is IGF-I-concentration and 
exposure-time dependent 
IGF-I or low oxygen tension stimulated ERK1/2 phosphorylation in both types of 
PMSCs; however, low oxygen tension reduced levels of the IGF-I mediated 
increase (Fig. S2.1C). p-ERK1/2 levels in P-PMSCs were unchanged with 
increasing concentrations of IGF-I in room air but decreased slightly under low 
oxygen tension (Fig. 2.5A). In T-PMSCs, ERK1/2 phosphorylation was increased 
by IGF-I in a dose-dependent manner (p<0.01, Pearson r =0.993) in room air 
(Fig. 2.5A, right), whereas the opposite was observed in low oxygen tension 
(p<0.05, Pearson r = -0.953). The phosphorylation pattern of ERK1/2 was time 
dependent, in P-PMSCs, the maximal increase in p-ERK1/2 occurred 1-hr after 
IGF-I stimulation under low oxygen tension (two-fold higher than in room air), and 
declined at 6-hrs (Fig. 2.5B, left). p-ERK1/2 levels increased again after 48-hrs if 
cells were maintained in low oxygen conditions (Fig. 2.5B, left). In T-PMSCs, p-
ERK1/2 levels were similar to P-PMSCs but at higher levels demonstrating a 
greater IGF-I response (Fig. 2.5B, right). 
 
Unlike p-ERK1/2, AKT phosphorylation was increased only by IGF-I especially 
under low oxygen tension in both types of PMSCs (Fig. 2.5C, left). p-AKT  
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FIGURE 2.4. The effect of low oxygen tension and IGF-I on phosphorylation 
of specific kinases. (A) The layout of major human cellular kinases in a 
phospho-kinase array, spotted in duplicates. (B) Phosphorylation changes in P-
PMSC whole cell lysate upon stimulation with or without IGF-I under room air or 
low oxygen for 15 min. (C) Immunoblots of IGF-IRα subunit, OCT4 and the two 
major phospho-kinases, ERK1/2 and AKT, following stimulation of PMSCs with 
IGF-I (100 ng/mL) for 15 min. (D) Quantification by densitometry of p-ERK1/2 
and p-AKT normalized to the respective total kinase and β-Actin. One-way 
ANOVA, P<0.05, n=3. * = significant difference by IGF-I. Similar results were 
seen with T-PMSCs. Low oxygen tension alone increased phosphorylation of 
ERK1/2 but not AKT. IGF-I increased phosphorylation of both ERK1/2 and AKT 
in both room air and low oxygen tension.  
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reached its maximal activation at 100 ng/mL IGF-I in P-PMSCs, and at 50 ng/mL 
in T-PMSCs, again showing sensitivity of T-PMSCs (Fig. 2.5C). Under room air, 
AKT phosphorylation was significantly higher in T-PMSCs, whereas the effect of 
low oxygen tension was observed predominantly in P-PMSCs. These results 
demonstrate a predominant effect of IGF-I on AKT activation compared to 
ERK1/2 under low oxygen. Concurrently, maximal AKT phosphorylation level 
was achieved at 15-60 min post IGF-I exposure in both PMSCs under room air 
(Fig. 2.5D). Low oxygen maintained higher levels of p-AKT, especially in P-
PMSCs, before reaching its lowest level at 48-hrs (Fig. 2.5D). 
 
Thus, in low oxygen tension, we observed a correlation between IGF-I mediated 
increase of OCT4 levels with a decrease in p-ERK1/2 and an increase in p-AKT. 
This can also be temporally regulated by the increased p-AKT and decreased p-
ERK1/2, especially seen in low oxygen tension in P-PMSCs. Therefore, IGF-I 
concentration and stimulation time control the signaling via p-ERK1/2 and p-AKT, 
which may directly correlate with multipotency and proliferation. 
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FIGURE 2.5. Oxygen tension modulates p-ERK1/2 and p-AKT in PMSCs in 
response to IGF-I concentration and exposure time. Phosphorylation of (A 
and B) ERK1/2 and (C and D) AKT were quantified by densitometry of 
immunoblots of P-PMSCs and T-PMSCs cell lysates. P- and T-PMSCs were 
stimulated with increasing concentration (0, 10, 50 and 100 ng/mL) of IGF-I for 
48-hrs or with IGF-I (100 ng/mL) over time 0-48-hrs under room air or low oxygen 
tension. Quantification by densitometry was normalized to the respective total 
kinase, β-Actin for protein load and DNA content to account for stem cell 
heterogeneity. Two-Way ANOVA, P<0.001, n=3, a = significant difference 
between room air and low oxygen tension; * = significant difference by different 
concentrations of IGF-I or stimulation time. IGF-I increased phosphorylation of 
ERK1/2 and AKT in both P- and T-PMSCs. Both ERK1/2 and AKT increased 
rapidly within 1 hr. p-ERK1/2 decreased acutely, whereas p-AKT response was 
more prolonged. Low oxygen tension prolonged ERK1/2 and AKT 
phosphorylation.  
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2.3.5. IGF-IR and IRS-1 levels and phosphorylation are modulated by 
oxygen tension and IGF-I concentration and stimulation time 
IGF-I signaling starts at the level of the receptor, IGF-IR. As a result, levels of 
IGF-IRα, the IGF-I binding extracellular subunit, were increased in serum free 
conditions, and decreased by IGF-I in a dose-dependent manner in both P- and 
T-PMSCs (Fig. 2.6A). In low oxygen tension, IGF-IRα was maintained higher 
even in presence of IGF-I (Fig 2.6A). Also, IGF-IRα was decreased upon 
increased stimulation time by IGF-I (Fig. 2.6B). However, low oxygen tension 
maintained a more stable level of IGF-IRα in both P- and T-PMSCs than the 
sharp decrease by 48-hrs in room air. IGF-IRβ phosphorylation was also 
manipulated by low oxygen tension in PMSCs (Fig. S2.3). Levels of p-IGF-IRβ 
were increased with increasing concentration of IGF-I (Fig. S2.3 A and B), with a 
higher phosphorylation in P-PMSCs in low oxygen tension. However, increasing 
the stimulation time decreased IGF-IRβ phosphorylation with a more stable level 
in low oxygen tension (Fig. S2.3 C and D). 
 
The signaling pathway via p-ERK1/2 or p-AKT is dependent on interacting 
adaptor molecules with the IGF-IR. IRS-1, a major interacting adaptor protein 
with p-IGF-IRβ, was not changed by increasing IGF-I concentration in P-PMSCs, 
whereas was increased in T-PMSCs in room air (Fig 2.6C). Low oxygen tension 
maintained higher IRS-1 levels independent of IGF-I in both PMSCs (Fig. 2.6C). 
IRS-1 levels were also dependent on the duration of IGF-I exposure time, which  
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FIGURE 2.6. Oxygen tension modulates IGF-IRα and IRS-1 levels in PMSCs 
in response to IGF-I concentration and exposure time. Levels of (A and B) 
IGF-IRα and (C and D) IRS-1 were quantified by densitometry of immunoblots in 
P-PMSCs and T-PMSCs. P- and T-PMSCs were stimulated with an increasing 
concentration (10, 50 and 100 ng/mL) of IGF-I for 48-hrs or in presence of IGF-I 
(100 ng/mL) over 0-48-hrs under room air or low oxygen tension. Quantification 
of immunoblots (presented in Fig. S2.2) by densitometry was normalized to β-
Actin for protein load and DNA content to account for stem cell heterogeneity. 
Two-Way ANOVA, P<0.001, n=3, a = significant difference between room air and 
low oxygen tension; * = significant difference by different IGF-I concentrations or 
stimulation time. Low oxygen tension maintained increased levels of IGF-IR and 
IRS-1 that were decreased by IGF-I and exposure time.  
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has peaked at 1 hr then decreased (Fig. 2.6D). Low oxygen tension, however, 
maintained a narrow decrease in IRS-1 levels.  
 
To understand the role of IRS-1 in IGF-I signaling, we checked two 
phosphorylation sites on IRS-1, p-Y896 for GRB2 binding upstream of p-ERK1/2 
(43), and p-Y612 for p85 subunit of PI3K upstream of p-AKT (44). 
Phosphorylation levels were different between pY612 and pY896. Low oxygen 
tension upregulated p-Y896 in P-PMSCs and less in T-PMSCs (Fig. S2.3 A and 
B), which correlated with a higher p-ERK1/2 and proliferation. The levels of p-
Y612 were more responsive to increase with IGF-I concentration (Fig. S2.3 A 
and B), which are required for the increased p-AKT activation levels seen in 
figure 2.5 (C and D). With increased exposure time, p-Y896 was increased 
(peaked at 12 and 48 hrs) in both PMSCs, whereas p-Y612 was increased 
gradually (a major peak by 12 hrs) but decreased at 48 hrs with a higher level in 
P-PMSCs (Fig. S2.3 C and D). These findings indicate that low oxygen tension is 
a dominant regulator to increase IGF-IR and IRS-1 and their phosphorylation 
levels in presence of IGF-I. These changes may explain the induced 
phosphorylation levels seen with p-ERK1/2 and p-AKT levels that correlates with 
a higher proliferation and multipotency. 
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2.3.6. Inhibition of ERK1/2 and AKT suppresses PMSC proliferation and 
OCT4 levels 
We inhibited signaling downstream of IRS-1 of either MEK1/2 or PI3K using 
U0126 and LY294002. In P-PMSCs, U0126 reduced p-ERK1/2 levels in the 
presence of IGF-I (100 ng/mL) (Fig. 2.7A, left), and increased p-AKT levels under 
low oxygen tension (Fig. 2.7B, left). LY294002 decreased p-AKT in both oxygen 
tension conditions, while IGF-I had no effect (Fig. 2.7D, left). LY294002 is not a 
strict inhibitor of PI3K/AKT pathway, because it also reduced the p-ERK1/2 levels 
(Fig. 2.7C, left). In T-PMSCs, U0126 had less inhibitory effect than in P-PMSCs 
in absence of IGF-I, while the inhibitory effect increased at higher concentrations 
of IGF-I (Fig. 2.7A, right). Also, LY294002 increased p-ERK1/2 levels and this 
effect was parallel to reduction in p-AKT levels, which were further 
downregulated by IGF-I (Fig. 2.7C and D, right).  
 
The physiological role of activating ERK1/2 and AKT in PMSCs was evaluated by 
proliferation assay. Both U0126 and LY294002 abolished the IGF-I stimulated 
proliferation in both P- and T-PMSCs (Fig. 2.8A and B; C and D, respectively) 
that was not due to induced apoptosis (Fig. S2.4). Low oxygen tension increased 
cell proliferation in the presence of both inhibitors but did not restore normal 
proliferation response by IGF-I (Fig. 2.8 A – D). Interestingly, LY294002 caused a 
greater decrease in cell proliferation regardless of IGF-I or oxygen tension (P < 
0.0001) (Fig. 2.8C and D). The decreased proliferation by the inhibitors was 
greater in presence of IGF-I suggesting that PMSC proliferation is dependent on 
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FIGURE 2.7. The effect of upstream MEK1/2 inhibition or PI3K inhibition on 
ERK1/2 and AKT phosphorylation PMSCs. (A and C) p-ERK1/2, (B and D) p-
AKT levels in P-PMSCs and T-PMSCs in the presence of U0126 (5 µM) or 
LY294002 (10 µM). Cells were treated with the inhibitor with or without IGF-I (100 
ng/mL) under room air or low oxygen tension. Phospho-kinase levels were 
normalized to both total level of kinase and to β-Actin. The dotted lines (set at 1) 
represent the levels of p-ERK1/2 and p-AKT in DMSO control. The comparison 
with DMSO control is present in the supplemental figures (S2.5 and S2.6). Two-
Way ANOVA, P<0.001, n=3. U0126 inhibited p-ERK1/2 while increased p-AKT in 
presence of IGF-I, especially under low oxygen tension. LY294002 inhibited p-
AKT and reduced the levels of p-ERK1/2 in presence of IGF-I.  
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FIGURE 2.8. Proliferation of P- and T-PMSCs in the presence of ERK1/2 or 
AKT pathway inhibitors. Proliferation of both (A and C) P-PMSCs and (B and 
D) T-PMSCs is shown by the WST1 assay. P- and T-PMSCs were grown in the 
presence of (5 μM) U0126 (A and B) or (10 μM) LY294002 (C and D) in varying 
concentrations of IGF-I (0, 10, 50, 100 ng/mL) under room air or low oxygen for 
48-hrs. The absorbance was measured at 450 nm with a background reference 
of 650 nm. Absorbance values were normalized to their matched DMSO controls. 
(Two-way ANOVA, P<0.05, n=8, a = significant difference between room air and 
low oxygen tension; * = significant difference by different IGF-I concentrations). 
PMSCs were not dying in response of inhibitor as shown in Figure S2.4. U0126 
and LY294002 inhibited IGF-I increased P- and T-PMSC proliferation. Low-
oxygen tension maintained a higher proliferation but could not rescue inhibition 
effect.  
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IGF-I signaling via MEK1/2 and PI3K, and eventually through p-ERK1/2 and p-
AKT. The augmented effect of low oxygen tension on proliferation was 
dependent on both signaling pathways. 
 
To determine if p-ERK1/2 and p-AKT are involved in multipotency, OCT4 levels 
were measured under low oxygen levels in presence of either U0126 or 
LY294002. Blocking p-ERK1/2 pathway did not affect OCT4 levels under low 
oxygen tension in both P- and T-PMSCs (Fig 2.9A), while blocking p-AKT 
decreased OCT4 levels in the presence of IGF-I (Fig. 2.9B). OCT4 was more 
sensitive to PI3K/AKT activation compared to MEK/ERK1/2 and it was restored in 
both types of PMSCs when p-AKT level was maintained or increased by U0126 
under low oxygen (Fig. 2.7B and 9A). We concluded that p-AKT is important in 
maintaining OCT4 expression and therefore multipotency, by IGF-I. 
 
2.4. DISCUSSION 
Unlike Embryonic stem cells (ESCs), MSCs show great promise for tissue 
regeneration therapies as they have less ethical controversies and are less 
tumorigenic in vivo (45). Also, MSCs have the immunomodulatory effect to 
reduce an immune response and to successfully engraft in graft versus host 
disease resistant patients (45, 46). However, a large number of MSCs is required 
for tissue regeneration therapies; therefore, optimization of in vitro culture 
conditions are needed to maintain multipotency  
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FIGURE 2.9. The effect of upstream MEK1/2 or PI3K inhibition on OCT4 
levels in P- and T-PMSCs in the presence of IGF-I and low oxygen tension. 
OCT4 levels from immunoblots of P-PMSCs and T-PMSCs in the presence of (A) 
U0126 (5 µM) or (B) LY294002 (10 µM) are shown. P- and T-PMSCs were 
treated with the inhibitor with or without IGF-I (100 ng/mL) under room air or low 
oxygen tension. OCT4 levels were normalized to total β-Actin levels. The dotted 
lines (set at 1) represent the levels of OCT4 in their respective DMSO control. 
The comparison with DMSO control is present in the supplemental figures (S2.7). 
Two-Way ANOVA, P<0.001, n=3. OCT4 levels were not affected by U0126, but 
were reduced by LY294002 especially under low oxygen tension.  
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and proliferation without inducing differentiation. This can be manipulated by 
understanding the natural microenvironment of the stem cell niche, which defines 
the structural, chemical, and biochemical factors (47, 48). In this study, we 
focused on the role of low oxygen tension in controlling the IGF-I mediated 
proliferation and multipotency of PMSC from early and term gestation placentae.  
Here, we demonstrated that PMSCs from early gestation (P-PMSCs) had a 
greater proliferation response to IGF-I and was enhanced by low oxygen tension 
(1%) in contrast to term gestation PMSCs (T-PMSCs). IGF-I and low oxygen 
major signaling was mediated mainly via p-ERK1/2 and p-AKT. Phosphorylation 
of p-AKT but not p-ERK1/2 in low oxygen tension was IGF-I-dependent. 
Multipotency, via OCT4 levels, was positively regulated by IGF-I concentration 
and stimulation time mainly via the signaling of p-AKT. Thus, IGF-I can mediate 
PMSC proliferation and multipotency from different gestations which is enhanced 
in low oxygen tension. 
 
Low oxygen tension culture conditions used in this study, which is usually defined 
as hypoxia in many in vitro experiments, is the normal physiological oxygen 
tension in stem cell niches, whereas room air (20% O2) used for standard cell 
culture is hyperoxic. Low oxygen tension found in many tissues ranges from ~ 
14.4 mm Hg to ~ 68.4 mm Hg (2 - 9% with a mean of 3%) (49-51) and can reach 
as low as 7.2 mm Hg (1%) in bone marrow (where hematopoietic stem cells 
reside), thymus or the kidney medulla due to atypical blood vessel network (51). 
In the placenta, oxygen tension at the endometrial surface starts low at 17.9 mm 
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Hg (~ 2.35% O2) prior to the establishment of utero-placental circulation and then 
rises up to 60 mm Hg (~ 7.9% O2) after connection with the maternal circulation 
(11). We, therefore, proposed that tissue culture conditions should physiologically 
mimic in vivo conditions in order to better understand PMSC proliferation and 
multipotency. 
 
ESCs exist in low oxygen tension conditions, and fertilization occurs in a hypoxic 
microenvironment (12, 52, 53). Culturing embryonic stem cells at low oxygen 
(1%) maintained a slower proliferation rate with a higher number of cells in the 
inner cell mass (ICM) and, more importantly, maintained greater pluripotency 
(higher OCT4 expression and SSEA markers) as compared to those maintained 
in ambient room air (51, 54). Therefore, low oxygen tension supports the full 
maintenance of pluripotency state of mammalian ESCs. PMSCs are typically 
isolated from term pregnancies (55-57); here, we isolated PMSCs from preterm 
pregnancies (11-13 weeks) with a hypothesis that P-PMSCs can have a higher 
multipotent state. Just like in ESCs, our results showed that low oxygen tension 
enhance both proliferation and OCT4 expression in P- and T-PMSCs. However, 
P-PMSCs expressed higher levels of OCT4 and proliferate at a higher rate in 
response to low oxygen tension compared to T-PMSCs. Hence, P-PMSCs may 
have more stemness than T-PMSCs; however, PMSCs from different gestations 
have a preserved proliferation and multipotency as tested by self-renewal 
markers and differentiation potential into several lineages (bone, adipose, 
endothelial and neuronal) (data not shown). 
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IGF-I, an important growth factor in mammalian development including the 
placenta, stimulates cell mitogenesis, differentiation and survival, primarily via 
IGF-IR (16, 58). In the placenta, there is no knowledge of the IGF-I concentration 
in the chorionic villi during different gestations; however, IGF-I concentration was 
measured at 71 – 132 ng/mL in the umbilical cord blood (10); therefore we used 
a concentration between 10 and 100 ng/mL. IGF signaling via the IGF-IR has 
been demonstrated to be crucial to mediate ESC multipotency and proliferation 
(17). However, the effect of IGF signaling under low oxygen tension conditions is 
not understood. Here, in PMSCs, IGF-I increased the proliferation capacity in 
both P- and T-PMSCs that was enhanced by low oxygen tension. We monitored 
OCT4 level as a marker of multipotency, which was shown to change stem cell 
identity when is changed by 50% of the required level for pluripotency (35). In 
PMSCs, low oxygen tension alone caused an increase in OCT4 levels compared 
to room air (Fig. S1B), while IGF-I alone increased OCT4 levels similar to FBS in 
room air (unpublished data). Also, P-PMSCs were less sensitive to increase 
OCT4 levels than T-PMSCs (12- vs. 6-hrs) in response to IGF-I compared to T-
PMSCs, which can be attributed to the already higher OCT4 expression in the 
more “naïve” P-PMSCs. 
 
In ESCs, signaling pathways such as RAS/MEK/ERK and PI3K/AKT are 
specifically upregulated and are required to confer an undifferentiated state via 
maintaining levels of OCT4, SOX2 and NANOG (59). In PMSCs, we identified 
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that p-ERK1/2 and p-AKT were the two major kinases activated by both low 
oxygen and IGF-I. ERK1/2 is a mitogen kinase that translocates to the nucleus 
when phosphorylated to further phosphorylate target genes (c-jun, Elk-1, RSK90, 
Myc, MNK, BRF-1, UBF, etc) to promote proliferation or differentiation (60). A 
recent discovery of 14 phosphorylation sites on OCT4 has revealed three 
putative phosphorylation sites for ERK2 at S111, T118, and S355 (61), which 
may play a role to maintain multipotency of stem cells. Also, a chromatin 
interaction of ERK2 is shown to be involved in pluripotency transcriptional 
machinery to interact with OCT4 promoter region with no clear function (62). 
AKT, on the other hand, is responsible for maintaining survival by inhibiting 
apoptosis via phosphorylating several targets (c-RAF, BAD, caspase-9, etc.), 
promoting cellular growth and protein translation (via mTORC1), and regulating 
glycogen synthesis (63). We demonstrated that low oxygen tension alone was 
able to intrinsically upregulate the p-ERK1/2 levels (promoting growth), whereas 
IGF-I was required for the phosphorylation of AKT (promoting survival) 
regardless of the oxygen tension. Also, low oxygen tension caused a global 
reduction in p-ERK1/2 levels in presence of IGF-I and a lowered sensitivity to 
activate AKT. In P-PMSCs, p-ERK1/2 decreased within a narrow range while, in 
T-PMSCs, it decreased in a dose-dependent manner with increasing 
concentrations of IGF-I under low oxygen tension. These gestational stage-
dependent differences in p-ERK1/2 and p-AKT activation patterns suggest that 
the maintenance of stemness of PMSCs, which is higher under low oxygen 
tension conditions, requires a steady active state of ERK1/2 and AKT signaling. 
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P- and T-PMSCs have similar abundance of IGF-IR and IRS-1 levels in response 
to IGF-I and low oxygen tension, however, they respond differently to IGF-I as 
demonstrated by p-ERK1/2 and p-AKT levels. It was shown previously in 293T, 
MEFs, 3T3-L1, and MCF-7 cells that IRS-1 is degraded through a caspase-
mediated cleavage mechanism, following a transient (1-6 hrs) exposure to low 
oxygen (1%) in the presence of IGF-I (64). In PMSCs, low oxygen tension 
increased the levels of IGF-IR and IRS-1 in contrast to room air. However, the 
longer exposure to IGF-I in low oxygen tension conditions decreased IGF-IR and 
IRS-1 to lower levels than room air. This can be a negative feedback mechanism 
to downregulate the higher phosphorylation signal at IGF-IRβ and IRS-1 seen in 
low oxygen tension. Moreover, phosphorylation of IGF-IRβ in low oxygen tension 
was higher in P-PMSCs than T-PMSCs even at higher IGF-I concentration, which 
can explain the higher proliferation level at 100 ng/mL. IRS-1 was 
phosphorylated at Y896 and Y612 in response to IGF-I, providing docking sites 
for upstream signaling cascades for ERK1/2 and AKT activation, respectively. 
Low oxygen tension increased higher p-IRS-1 at Y896 and Y612 in P-PMSCs 
than in T-PMSCs. This demonstrates that low oxygen tension can mediate an 
increased availability of IGF-IR and IRS-1 with more binding sites for p-ERK1/2 
and p-AKT signaling, especially in P-PMSCs, which have higher proliferation and 
OCT4 levels. 
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Inhibition of the activation of ERK1/2 and AKT led to decreased responsiveness 
to IGF-I in both P- and T-PMSCs, which was negatively impacted by low oxygen 
tension. It has been shown in ESCs that PI3K inhibition leads to differentiation by 
reducing OCT4 expression, while MEK1/2 inhibition caused the same effect, but 
less prominently (59). In addition, suppression of p-ERK1/2 sustains a basal 
state of pluripotency, and therefore conversely, increased p-ERK1/2 levels, 
should lead to differentiation (65). These previous findings support our findings in 
PMSCs, where we showed that inhibition of PI3K promoted the reduction of 
OCT4 levels and cellular proliferation that was greater than the inhibition of 
MEK1/2. The PI3K inhibitory effect could not be restored by IGF-I in both types of 
PMSCs and low oxygen tension enhanced the effect. As shown in ESCs (59), the 
MEK/ERK signaling pathway can potentially be downstream of the PI3K signaling 
in PMSCs, as LY294002 also reduced the levels of p-ERK1/2. The inhibition of 
MEK/ERK pathway increased p-AKT levels, especially under low oxygen tension 
conditions, demonstrating a possible compensatory mechanism for the reduced 
levels of p-ERK1/2 necessary to maintain PMSC proliferation and multipotency. 
These findings suggest that for the maintenance of multipotency, PMSCs should 
be maintained under low oxygen tension with activated PI3K/AKT signaling, 
perhaps by IGF-I.  
 
This study provides an insight into the role of the microenvironment, especially 
low oxygen tension, in directing receptor tyrosine kinase signaling by modifying 
abundance of effector kinases and signal intensity in response to growth factors, 
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e.g. IGF-I. This knowledge of signaling pathways will allow for in vitro stem cell 
preconditioning by growth factors, oxygen tension and chemical molecules for a 
more successful use in tissue regeneration therapies mimicking that of in vivo 
conditions for better engraftment and survival.  
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Appendix 1 
 
FIGURE S2.1. Low oxygen tension increases PMSC proliferation in 
response to IGF-I. (A) P-PMSC (B) T-T-PMSC proliferation was assessed using 
the Countess Cell counter. P- and T-PMSCs were treated with increasing IGF-I 
concentrations (0, 10, 50,100 ng/mL) in room air or low oxygen tension for 48-
hrs. Two-Way ANOVA, P<0.05, n=6; a = significant difference between room air 
and low oxygen tension, * = significant difference by different IGF-I 
concentrations. In both P- and T-PMSCs, low oxygen tension enhanced the 
effect of IGF-I on cellular proliferation.  
C) Immunoblotting of p-ERK1/2 and p-AKT in Pre-term and Term PMSCs. p-
ERK1/2 is reduced in low oxygen tension below that in room air and sensitivity to 
induce p-AKT activation is reduced to higher IGF-I concentrations.  
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Appendix 1 
 
FIGURE S2.2. IGF-IR and IRS-1 levels in response to IGF-I stimulation under 
low oxygen tension is dose and time dependent. (A and B) Immunoblots of 
IGF-IRα and total IRS-1 levels following treatment with different concentrations of 
IGF-I (0, 10, 50, 100 ng/mL) in both P- and T-PMSCs for 48-hrs. (C and D) 
Immunoblots IGF-IRα and IRS-1 levels in P-PMSCs and T-PMSCs following 
treatment with IGF-I (100 ng/mL) over 48-hrs under room air and low oxygen 
tension (n=3). β-Actin levels indicate equivalent protein loading. Low oxygen 
tension enhance an increased level of IGF-IRα and IRS-1 in both PMSCs. IGF-
IRα and IRS-1 levels decrease with increased concentration of IGF-I or 
stimulation time.      
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FIGURE S2.3. Oxygen tension modulates the phosphorylation of IGF-IRβ 
and IRS-1 (pY612 and pY896) levels in PMSCs. (A and C) P- and (B and D) T-
PMSCs were stimulated with an increasing concentration (0, 10, 50, 100 ng/mL) 
of IGF-I or with IGF-I (100 ng/mL) over 0-48-hrs under room air or low oxygen 
tension, respectively. Levels of p-IGF-IRβ, p-IRS-1pY-896and p-IRS-1pY-612 were 
quantified by densitometry of immunoblots in P-PMSCs and T-PMSCs. 
Quantification by densitometry was normalized to β-Actin for protein load and 
DNA content to account for stem cell heterogeneity. Two-Way ANOVA, P<0.001, 
n=3, a = significant difference between room air and low oxygen tension, * = 
significant difference by increased IGF concentration or stimulation time.  
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FIGURE S2.4. Assessment of use of MEK1/2 and PI3K inhibitor 
concentrations. Immunoblots of pro-caspase-9, activated caspase-9 and PCNA 
in preterm PMSCs after 48-hrs treatment. Cells were treated continually in 
presence of U0126 or LY294002 for 48-hrs in presence or absence of IGF-I (100 
ng/mL) to assess apoptosis (caspase-9) and proliferation (PCNA) (n=3). 
Concentration of inhibitors was assessed based on highest concentration of 
inhibitor that does not induce apoptosis.  
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FIGURE S2.5. Effect of MEK1/2 and PI3K inhibition on p-ERK1/2 in PMSCs 
under low-oxygen. (A) P-PMSCs and (B) T-PMSCs (N=2) were treated in 
presence of U0126 (5 μM) or LY294002 (10 μM) in combination IGF-I (0 or 100 
ng/mL) for 48-hrs under room-air or low-oxygen. Immunoblots of p-ERK1/2 were 
normalized to total kinase level and β-ACTIN. DMSO is a vehicle control. (One-
way ANOVA, p<0.05, n=3, * = significant difference compared with DMSO control 
at 0 ng/mL IGF-I).  
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FIGURE S2.6. Effect of MEK1/2 and PI3K inhibition on p-AKT in PMSCs 
under low-oxygen. (A) P-PMSCs and (B) T-PMSCs (N=2) were treated in 
presence of U0126 (5 μM) or LY294002 (10 μM) in combination IGF-I (0 or 100 
ng/mL) for 48-hrs under room-air or low-oxygen. Immunoblots of were 
normalized to total kinase level and β-Actin. DMSO is a vehicle control. (One-way 
ANOVA, p<0.05, n=3, * = significant difference compared with DMSO control at 0 
ng/mL IGF-I).  
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FIGURE S2.7. Effect of MEK1/2 and PI3K inhibition on OCT4 expression as 
a marker for stemness in PMSCs under low-oxygen. A) P-PMSCs and (B) T-
PMSCs (N=2) were treated in presence of U0126 (5 μM) or LY294002 (10 μM) in 
combination IGF-I (0 or 100 ng/mL) for 48-hrs under room-air or low-oxygen. 
Immunoblots of were normalized to β-Actin. DMSO is a vehicle control. (One-way 
ANOVA, p<0.05, n=3, * = significant difference compared with DMSO control at 0 
ng/mL IGF-I).  
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CHAPTER THREE 
Low Oxygen Tension Modulates the Insulin-like Growth Factor Signaling 
via Insulin-like Growth Factor-I Receptor and Insulin Receptor to Maintain 
Stem Cell Identity in Placental Mesenchymal Stem Cells 
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3.1 INTRODUCTION 
Manipulating stem cells in vitro is a critical process to preserve stem cell identity 
and induce fate changes towards self-renewal or differentiation (1). For tissue 
regeneration therapy, it is important to prolong the characteristics of stem cell in 
vitro which can be achieved by mimicking their natural microenvironment (growth 
factors, extracellular matrices, oxygen tension, etc.) before their use for 
successful in vivo applications (2, 3). Insulin-like growth factors (IGFs; IGF-I and 
IGF-II) and oxygen tension are major stem cell niche factors in the human 
placenta (4, 5). IGFs are known to manipulate stem cell fate to maintain 
multipotency or induce differentiation, while continuous low oxygen tension 
microenvironment inhibits stem cell differentiation and retain multipotency (6-9). 
 
The use of IGF-I and IGF-II has become popular in cell culture systems to 
maintain self-renewal or induce differentiation. IGF-I and IGF-II are polypeptide 
ligands, similar to pro-insulin, that signal through the IGF-IR, a RTK, to trigger a 
mitogenic response through the ERK1/2 and the AKT pathways to promote 
growth and survival and inhibit apoptosis (4, 10, 11). Moreover, both IGF-I and -II 
can signal through the IR or hybrid IGF-IR/IR receptor (12, 13). IGF-IR is more 
sensitive to IGF-I with a Kd of 1 nM and with a 10-fold lower affinity to IGF-II (14). 
In ES cells, IGF-IR is highly enriched and is required to maintain stem cell self-
renewal and pluripotency as blocking the IGF-IR reduced pluripotency and even 
induced differentiation (8, 9, 15). The use of IGF-I (200 ng/mL) in defined DC-
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HAIF media (15) or IGF-II (30 ng/mL) in KOSR media (8) was sufficient to 
maintain undifferentiated hESCs in vitro without the need for a feeder layer. 
 
OCT4, NANOG and SOX2 constitute a triad of transcription factors, which 
regulate human ES cell fate. They are also utilized to generate iPSCs (16-19). 
Each of these transcription factors has a major role in repressing the 
differentiation process towards a specific lineage: OCT4 represses 
extraembryonic and epiblast-derived lineages, NANOG represses embryonic 
ectoderm differentiation, and SOX2 represses mesendoderm differentiation (16). 
In vivo, stem cells reside in a compartment with low oxygen levels (3 - 5% O2). 
Therefore, low oxygen tension is an important factor modulating stem cell 
identity. In hESCs, the hypoxia inducible factor 2 (HIF2), formed in low oxygen 
tension, can interact with the promoter regions of OCT4, NANOG and SOX2 and 
enhance their expression (20, 21). Even, when generating iPSCs, low oxygen 
tension enhances reprogramming efficiency by increasing the number and size of 
colonies and their expression of pluripotency genes. It is possible to form 
colonies in absence of one or two of the four-transcription factors (Oct3/4, Klf4, 
+/- Sox2, +/- c-Myc) only if placed in low oxygen tension (22). Therefore, it is 
becoming important to culture ESCs, MSCs and iPSCs in low oxygen tension as 
it may modulate cell response to intracellular/extracellular growth factors in order 
to maintain stem cell character similar to in vivo conditions.  
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In this context, the interaction of IGFs with their receptors (IGF-IR vs. IR) in the 
stem cells is not clear and whether low oxygen tension can modify stem cell 
multipotency. For this purpose, we used placental mesenchymal stem cells 
(PMSCs) as a model to study the differences between IGF-I and IGF-II signaling 
at low oxygen tension, a microenvironment that mimic the placenta in vivo. We 
hypothesized that, under physiological low oxygen tension, IGF-I and IGF-II 
regulate PMSC self-renewal capacity by utilizing different signal transduction 
mechanisms via the IGF-IR. Here, we show how oxygen tension can distinctly 
upregulate IGF-II expression and abundance. Also, we demonstrate that IGF 
signaling via its receptor mediates PMSC signaling through ERK1/2 and AKT to 
promote increased PMSC proliferation. Low oxygen tension upregulated the 
expression of OCT4, NANOG and SOX2, which were lowered by IGF stimulation. 
We also propose that, besides the IGF-IR, an important role of the IR becomes 
prominent in enhancing PMSC proliferation under low oxygen tension conditions.  
 
3.2. MATERIAL AND METHODS 
3.2.1. PMSC Isolation 
PMSCs were isolated from early gestation human placentae - from 10-13 weeks. 
For comparison between gestational ages, PMSCs were isolated from mid 
gestation 20-22 week or from late gestation 37-40 weeks. After informed 
consent, placentae were collected from patients who underwent therapeutic 
pregnancy termination. Immediately after surgery, placentae were dissected 
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under sterile conditions and small pieces of chorionic villi were collected. Tissue 
samples were minced mechanically and subjected to a process consisting of two 
steps of enzymatic digestion with (1) collagenase IV/hyaluronidase, and (2) 
DNase I followed by (3) trypsin/EDTA. Each enzymatic step was performed for 
10 min at 37ºC, followed by 10 min wash at 4ºC in a solution of PBS 
supplemented with 10% fetal bovine serum (FBS) (Gibco, Mississauga, ON, 
CAN). Cells released during digestion were passed through a tissue mesh (45 
μm) to obtain a single cell suspension. Next, cells were separated on a Percoll 
(Sigma) discontinuous gradient according to a modified protocol by Worton et al. 
for hematopoietic stem cell isolation (23) and then seeded in DMEM/F12 media 
(Gibco, Mississauga, ON, CAN) supplemented with 15% FBS, FGF-2 (100 
ng/mL) and antibiotic-antimycotic solution (1x). After 4 days, media was changed 
and non-adherent cells were washed with media to leave behind adherent 
PMSCs able to form colonies.  
 
3.2.2. Cell Culture and Incubation in Low Oxygen Tension 
For each experiment, two preterm PMSC cell populations were used in triplicate. 
Cells were cultured and maintained using DMEM/F12 media supplemented with 
15% FBS and FGF-2 (100 ng/mL) (Gibco, Mississauga, ON, CAN). Before 
treatments, cells were cultured in DMEM/F12 supplemented 10% FBS only. 
Upon treatment, PMSCs were switched to fresh media containing only IGF-I or 
IGF-II (0 – 100 ng/mL). For IGF-IR or IR neutralization experiments, cells were 
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grown in serum-free media for 24-hrs and then specific antibodies were added at 
a final concentration of 5 µg/ml in serum-free media. Then, 50 ng/ml of IGF-I or 
IGF-II final concentration was added to the cell-culture for 24-hrs. Cell cultures 
were then placed in either a 5% CO2 incubator or a hypoxia chamber, which was 
filled with a mix of (1% O2, 5% CO2, Balanced N2) (BOC Canada Ltd, Toronto, 
ON, CAN) for 15 min to ensure saturation using a Hudson 5590 Oxygen Monitor 
(Hudson, Ventronics Division, Temecula, CA, USA). Thereafter, the chamber 
was placed in a tissue-culture incubator at 37o C.  
 
3.2.3. Real-time PCR 
Total RNA was extracted from PMSCs using the PureLink RNA Mini Kit (Ambion, 
Burlington, ON) as per the manufacturer’s protocol. Cells cultured in 60 mm 
dishes were lysed in lysis buffer with 1% β-mercaptoethanol. Lysates were 
scraped, collected in 1.5 mL tubes and homogenized using 21-gauge syringe 
needle (10 times). Lysates were then applied to the column for binding RNA, 
washed and eluted using RNase free water. 1-3 µg total RNA were reverse 
transcribed into cDNA using Superscript III first-strand synthesis system for RT-
PCR (Invitrogen, Burlington, ON, CAN) and (25 μM) oligo (dT)20 primers in 20 µL 
volume. Quantitative PCR was performed on 100 ng of cDNA using Platinum 
SYBR-Green qPCR SuperMix-UDG with ROX (Invitrogen, Burlington, ON, CAN) 
following the manufacturer protocol. PCR products were less than 200 bp and 
each primer concentration used was 0.4µM. All reactions were run in 10µL in 
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384-well plate format using the Applied Biosystems ViiA 7 System. Human 
RPL13a gene was used as the reference endogenous control for normalization of 
the target genes. Standard curves were generated with 5 points of cDNA (500-
0.05 ng/µL) besides runs without template as a negative control (NTC). 
Amplifications conditions were run at 50°C for 2 min, 95°C for 10 min followed by 
40 cycles of 95°C for 30 sec, 60°C for 30 sec and 72°C for 15 sec. The following 
primers were used: IGF-I sense (5’- CCT CCT CGC ATC TCT TCT ACC TG-3’), 
antisense (5’-CTG CTG GAG CCA TAC CCT GTG-3’); IGF-II sense (5’-CGG 
CTT CTA CTT CAG CAG GC-3’), antisense (5’-TGG CGG GGG TAG CAC AGT-
3’); IGF-IR sense (5’-GAG CAG CTA GAA GGG AAT TAC-3’), antisense (5’-AAG 
TTC TGG TTG TCG AGG A-3’); IR-A sense (5’-GTT TTC GTC CCC AGG CCA 
TC-3’), antisense (5’-CCA ACA TCG CCA AGG GAC CT-3’); IR-B sense (5’-CAC 
TGG TGC CGA GGA CCC TA-3’), antisense (5’- GAC CTG CGT TTC CGA GAT 
GG-3’); OCT4 sense (5’-GAT GTG GTC CGA GTG TGG TTC T-3’), antisense 
(5’-TGT GCA TAG TCG CTG CTT GAT-3’); SOX2 sense (5’-TTG CTG CCT CTT 
TAA GAC TAG GA-3’), antisense (5’-CTG GGG CTC AAA CTT CTC TC-3’); 
NANOG sense (5’-ATG CCT CAC ACG GAG ACT GT-3’), antisense (5’-AAG 
TGG GTT GTT TGC CTT TG-3’)RPL13a sense (5’-CAT AGG AAG CTG GGA 
GCA AG-3’), antisense (5’-GCC CTC CAA TCA GTC TTC TG-3’). 
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3.2.4. Immunoblotting 
Cell lysates were prepared using 1x cell lysis buffer for phospho-proteins 
according to manufacturer protocol (#9803, Cell Signaling Technologies, 
Burlington, ON, CAN). Protein samples (10-20 µg each) were resolved by 10% 
SDS-PAGE, and then transferred onto PVDF membranes (Millipore, Bedford, 
MA). The membranes were blocked with 5% bovine-serum-albumin or in 5% 
non-fat-dry milk in 1x TBS (Tris-buffered saline) for 1 hr at room temperature. 
Blots were then washed in 1x TBS 0.1% Tween 20 (TBS-T) (3x for 5 min) 
followed by incubation at 4oC overnight with primary antibodies as per 
manufacturer’s protocols. Blots then were washed using TBS-T (3x for 10 min) 
and were incubated with the corresponding secondary HRP-labelled antibody for 
1 hr at RT. Immunocomplexes were detected by ECL and documented using 
VersaDOCTM Imaging System (Bio-Rad). 
 
3.2.5. Antibodies 
To investigate the IGF-I vs. IGF-II activated signaling proteins in PMSCs, we 
used the following antibodies: phospho-p44/42 MAPK (#4377), p44/42 MAPK 
(#9102) phospho-AKT (Ser473, #4051), AKT (#9272) and p-IGF-IRβ (#3918) 
from (Cell Signaling Technologies, Burlington, ON, CAN) and IGF-IRα (N-20, sc-
712) and IGF-IRβ (C-20, sc-713) (Santa Cruz Biotech., Santa Cruz, CA, USA). 
For receptor neutralization, we used IGF-IRα (1H7, sc461-L) (Santa Cruz 
Biotech., Santa Cruz, CA, USA) and IRα (MA-20, NB400-142) (Novus Canada, 
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Oakville, ON, CAN). For multipotency markers, we used OCT3/4 antibody (N-19, 
sc-8628) (Santa Cruz Biotech., Santa Cruz, CA, USA), SOX-2 (2683-1) and 
NANOG (3369-1) (Epitomics, Burlington, ON, CAN). For loading control, we used 
pan-Actin Ab-5 (#MS-1295) (Thermo Fisher Scientific, Fremont, CA). The 
secondary antibodies used for immunoblotting were goat anti-rabbit (#170-6515), 
anti-mouse (#170-6516) HRP conjugated antibodies (BioRad laboratories, 
Hercules, CA) or donkey anti-goat antibody (sc-2020) Santa Cruz Biotech., Santa 
Cruz, CA, USA).  
 
3.2.6. Statistical Analysis 
All experiments were run in triplicates from three independent experiments each; 
whenever possible three or more PMSC primary lines were used. All graphs and 
analyses were generated using GraphPad Prism Software 5.0 (GraphPad 
Software, San Diego, CA). A Two-way ANOVA with Bonferroni post hoc test was 
used for the PMSC WST1 proliferation assay and densitometry quantifications. 
Data are expressed as mean ± standard error of the mean (SEM); values were 
considered significant when p<0.05. 
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3.3. RESULTS 
3.3.1 PMSC expression of IGF-I and IGF-II is controlled by oxygen tension 
and IGF stimulation  
During placental development in vivo, IGFs are expressed differentially with 
gestation - IGF-II is expressed earlier and in higher abundance than IGF-I (24). 
This expression pattern was confirmed by PMSCs isolated from different 
gestational ages only when maintained under low oxygen tension to express 
higher IGF-II at early gestation and a later expression of IGF-I (Fig. S3.1). In this 
study, the experiments were conducted using preterm PMSCs isolated from early 
pregnancies only. They have higher levels of OCT4, the master regulator switch 
of pluripotency (Fig. S3.2). IGFs are mainly secreted by the liver as endocrine 
signaling factors but they are also produced in peripheral tissues as 
autocrine/paracrine factors, which contribute to tissue maintenance, growth and 
repair. In PMSCs, extracellular IGF-I stimulation increased IGF-I expression in 
room air at 100 ng/mL (positive feedback). There were no change in expression 
under low oxygen tension conditions, which demonstrated lowered basal IGF-I 
expression compared to room air (Fig. 3.1A). Similarly, extracellular IGF-II 
stimulation (10 and 50 ng/mL) increased IGF-I expression under room air (Fig. 
3.1B). Low oxygen tension increased IGF-II expression (≥ 2-fold) that was also 
increased by extracellular IGF-I (50 and 100 ng/mL) in low oxygen tension (Fig. 
3.1C). With extracellular IGF-II stimulation, IGF-II expression increased in a dose 
dependent response in presence of IGF-II only in low oxygen tension (Fig. 3.1D). 
Therefore, expression of IGFs by PMSCs is dependent on oxygen tension - low  
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FIGURE 3.1. Expression of IGF-I and -II mRNA by PMSCs is regulated by 
exogenous IGF and low oxygen tension. PMSCs were cultured for 48-hrs in 
either room-air or low-oxygen tension in presence or absence of IGF-I or IGF-II 
(0, 10, 50, 100 ng/mL). By real-time PCR, expression level of IGF-I and -II mRNA 
were measured relative to RPL13a as an endogenous control. IGF-I levels were 
measured with increasing concentration of A) IGF-I or B) IGF-II. Similarly, IGF-II 
mRNA levels are shown in presence of increasing concentrations of C) IGF-I or 
D) IGF-II. (Two-way ANOVA, p<0.05, n=3, *= significant difference between room 
air and low oxygen tension; a= significant difference of different IGF 
concentrations in room air, A= significant difference of different IGF 
concentrations in low oxygen tension). Low oxygen tension decreased IGF-I 
expression and increased IGF-II expression in PMSCs.  
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oxygen tension represses the expression of IGF-I, while it promotes the 
expression of IGF-II. Both are enhanced by extracellular IGFs in an oxygen 
tension-dependent manner.  
 
3.3.2. IGF-IR and IR expression is dependent on oxygen tension and IGF 
concentration 
PMSCs expressed both IGF-IR and IGF-IIR, and the IR, but the IGF actions are 
mediated through either the IGF-IR or IR to trigger mitogenic or metabolic 
actions. We noted that IGF-IR and IR (α-subunit) levels were upregulated in 
absence of IGFs and even more when combined with low oxygen tension (Fig. 
3.2). In room air, the increased concentration of IGF-I or -II decreased both 
receptor (IGF-IR and IR) protein levels in a dose dependent manner (more with 
IGF-I than IGF-II) (Fig. 3.2 C-F), but low oxygen tension had a significant 
opposing effect maintaining higher levels even in presence of IGFs (less with 
IGF-I) (Fig. 3.2 C-F). The decrease in the IR levels was less than IGF-IR in 
response to IGFs and the IR was increased in low oxygen tension even in 
presence of IGFs. At the receptor expression level, IGF-IR receptor mRNA was 
increased in low oxygen tension which was also decreased by IGF-I and -II (Fig. 
S3.3A and B). PMSCs also expressed the two isoforms of IR (IR-A and IR-B) 
(Fig. S3.3 C-F); however, low oxygen tension increased IR-A expression several 
fold compared with the IR-B. 
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 FIGURE 3.2. IGF-IR and IR levels are decreased by IGF-I and -II but elevated 
by low oxygen tension. PMSCs were cultured for 48-hrs in either room air or 
low oxygen tension in presence or absence of IGF-I or IGF-II (0, 10, 50, 100 
ng/mL). By Immunoblotting, protein expression levels of IGF-IRα or IRα was 
detected in presence of increasing concentration of A) IGF-I or B) IGF-II. The β-
subunits of both receptors showed similar protein levels with the different 
treatments. C-F) blot quantifications for both receptors are shown. β-Actin is used 
as a protein loading control. (Two-way ANOVA, p<0.05, n=3, *= significant 
difference between room air and low oxygen tension; a= significant difference of 
different IGF concentrations in room air, A= significant difference of different IGF 
concentrations in low oxygen tension). Low oxygen tension maintained higher 
levels of both receptors that were otherwise decreased with increasing 
concentration of IGFs in room air.    
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In the presence of IGF-II (100 ng/mL), IR-A level was decreased in low oxygen 
tension; this was similar to IR-B abundance (Fig. S3.3D and F). Therefore, the 
expression profile and protein levels of the IR was similar to IGF-IR response in 
the presence of IGFs, indicating that similar signaling mechanism controls IGF-IR 
and IR in PMSCs from early gestation placentae. Also, low oxygen tension 
opposed the negative regulation of IGF-IR or the IR by IGFs; the increased IGF-
IR or IR expression would allow increased responsiveness to IGFs. 
 
3.3.3. Activation of IGF-IR signaling pathway in PMSCs is regulated by 
oxygen tension 
IGF-I and IGF-II bind and activate the IGF-IR, but due to binding affinity, IGF-IR 
phosphorylation and activation varies especially in short term stimulation. In room 
air, the phosphorylation of the IGF-IR (β-subunit) was more sensitive to IGF-I 
than IGF-II (Fig. 3.3), whereas in low oxygen tension the sensitivity to IGF-I or 
IGF-II was decreased (Fig. 3.3A and B).  
The propagation of IGF-IR activation following short-term stimulation was tested 
via the phosphorylation of major signaling kinases downstream, ERK1/2 and 
AKT. In room air, ERK1/2 phosphorylation was similar with either IGF-I or -II (Fig. 
3.4A and B). However, low oxygen tension caused an increase in p-ERK1/2 
levels in response to IGF-I greater than that induced in room air (Fig. 3.4A). The  
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FIGURE 3.3. IGF-IR phosphorylation is dependent on IGF ligand, 
concentration and oxygen tension. PMSCs were stimulated for 15 min in 
either room air or low oxygen tension in presence or absence of A) IGF-I or B) 
IGF-II (0, 10, 50, 100 ng/mL) following serum deprivation for 24-hrs. From 
immunoblotting shown, levels of p-IGF-IRβ were quantified and normalized to 
total IGF-IRβ level followed by normalization to β-Actin, used as a protein loading 
control. (Two-way ANOVA, p<0.05, n=3, a= significant difference of different IGF 
concentrations in room air, A= significant difference of different IGF 
concentrations in low oxygen tension). Low oxygen tension deceased the levels 
of IGF-IR phosphorylation/activation making it less sensitive to IGF-I or -II.  
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FIGURE 3.4. ERK1/2 and AKT phosphorylation in PMSCs is dependent on 
IGF concentration and oxygen tension. PMSCs were stimulated for 15 min or 
48-hrs in either room air or low oxygen tension in presence or absence of IGF-I 
or IGF-II (0, 10, 50, 100 ng/mL). From Immunoblotting, detected levels of (A – D) 
p-ERK1/2 and (E – H) p-AKT were quantified and normalized to total kinase level 
and to β-actin, used as a protein loading control. (Two-way ANOVA, p<0.05, n=3, 
*= significant difference between room air and low oxygen tension; a= significant 
difference of different IGF concentrations in room air, A= significant difference of 
different IGF concentrations in low oxygen tension). In short term, Low oxygen 
tension potentiates p-ERK1/2 signal and represses p-AKT. In long term, Low 
oxygen tension, maintains lower p-ERK1/2 than room air and elevated p-AKT 
levels similar to room air.  
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IGF-II effect was not seen in low oxygen tension (Fig. 3.4B). AKT 
phosphorylation was more sensitive to IGF-I, similar to IGF-IRβ phosphorylation. 
In room air, AKT phosphorylation plateaued at 50 ng/mL of IGF-I while IGF-II 
induced the highest activation at 100 ng/mL (Fig. 3.3E and F). On the other hand, 
low oxygen tension lowered the phosphorylation levels of AKT in a similar pattern 
to p-IGF-IRβ (Fig. 3.4E and F). Overall, low oxygen tension reduced the 
phosphorylation of IGF-IRβ and AKT in a similar manner, and increased the 
phosphorylation of ERK1/2 in presence of IGF-I. 
Long-term phosphorylation of ERK1/2 and AKT can be indicators of stem cell 
state of proliferation. Continuous stimulation of PMSCs by IGF-I and -II in room 
air, caused a dose-dependent decrease in p-ERK1/2 levels similar to low oxygen 
tension (Fig. 3.4C and D). Phospho-AKT had an opposite activation pattern 
compared with p-EKR1/2 that caused a dose dependent increase with IGF-I or -II 
in both oxygen tensions (IGF-I being more potent than IGF-II) (Fig. 3.4G and H). 
Therefore, low oxygen can maintain a narrow range of p-ERK1/2 levels but does 
not interfere with p-AKT pathway that is dependent on IGF stimulation.  
 
3.3.4. Expression of stem cell-associated genes in PMSCs is regulated by 
low oxygen tension and IGFs  
Stem cell fate is determined by their microenvironment, and the expression of the 
pluripotency genes, OCT4, NANOG and SOX2, determines the character of 
stemness in hESCs and iPSCs. In PMSCs, all three genes are expressed and 
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regulated by low oxygen tension and IGFs. Low oxygen tension increased OCT4, 
NANOG and SOX2 mRNA levels and was decreased by IGFs (Fig. S3.4). 
However, IGFs maintained a higher expression of the three genes in low oxygen 
tension condition only (IGF-II more prominent than IGF-I to enhance expression 
72-hrs post stimulation) (Fig. S3.5). Transcription factors function at the protein 
level as they physically interact with DNA to regulate multipotency gene 
expression and fate changes. OCT4 protein levels did not change with increasing 
concentrations of IGF-I or IGF-II in either room air or low oxygen tension (Fig. 
3.5A). However, SOX2 and NANOG expression was affected by IGF-I or IGF-II 
at both mRNA and protein. Levels of NANOG and SOX2 were increased at 10 
ng/mL IGF-I and IGF-II then decreased in presence of increased concentrations 
of IGF-I or IGF-II (Fig. 3.5B and C). Therefore, OCT4 was unchanged by IGF and 
oxygen tension, although it was reduced at the mRNA level at increasing IGF-I. 
NANOG and SOX2 were elevated by low oxygen tension and decreased by IGF-I 
but not IGF-II stimulation. This shows that low oxygen tension can maintain or 
enhance multipotency but IGF-I and less with IGF-II (depending on concentration 
and stimulation time) oppose this effect. 
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FIGURE 3.5. NANOG and SOX2 but not OCT4 are decreased by IGFs and 
increased by low oxygen tension in PMSCs. PMSCs were stimulated for 48-
hrs in either room air or low oxygen tension in presence or absence of IGF-I or 
IGF-II (0, 10, 50, 100 ng/mL). From Immunoblotting, detected levels of A) OCT4, 
B) NANOG and C) SOX2 were quantified and normalized to β-actin, used as a 
protein loading control. (Two-way ANOVA, p<0.05, n=3, *= significant difference 
between room air and low oxygen tension; a= significant difference of different 
IGF concentrations in room air, A= significant difference of different IGF 
concentrations in low oxygen tension). Low oxygen tension was able to elevate 
the levels of NANOG or SOX2 but not OCT4, whereas increased IGF 
concentration caused a decrease in total levels.  
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3.3.5. PMSC proliferation is enhanced by IGFs in low oxygen tension 
Self-renewal is an important stem cell characteristic. We assessed PMSC 
proliferation as an indicator of self-renewal by oxygen tension and IGF-I or IGF-II 
concentration. In room air, IGF-I stimulated proliferation in a dose dependent 
manner that plateaued at (50 ng/mL), but was increased further if maintained in 
low oxygen tension (Fig. 3.6A). Interestingly, proliferation decreased when 
concentrations greater than 100 ng/mL of IGF-I was added in room air, but not in 
low oxygen tension (data not shown). In comparison, the effect of IGF-II was 
lower than that of IGF-I on PMSC proliferation in room air and was enhanced by 
low oxygen tension (Fig. 3.6B). Therefore, IGF-I is more potent in stimulating 
PMSC proliferation in room air, whereas, low oxygen tension potentiates both 
IGF-I and -II signaling to stimulate increased proliferation. These results show 
that a lowered p-ERK1/2 and increased p-AKT levels (Fig. 3.4) correlates with an 
IGF-stimulated proliferation. 
 
3.3.6. Low oxygen tension mediates a differential IGF signaling through the 
IGF-IR and IR to stimulate proliferation  
Low oxygen tension upregulated IGF-IR and IR expression. In room air, 
neutralizing the IGF-IR abolished the effect of IGF-I or -II stimulation; however, in 
low oxygen tension, the IGF-mediated proliferation remained elevated even in 
the presence of a 10-fold excess of antibody (Fig. S3.6). This finding suggests  
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FIGURE 3.6. PMSC enhanced proliferation in response to IGF-I or IGF-II is 
dependent on oxygen tension and specific receptor stimulation. PMSC 
proliferation was assessed using the WST-1 colorimetric proliferation assay in 
presence of increasing concentration of A) IGF-I or B) IGF-II (0, 10, 50, 100 
ng/mL) under room air or low oxygen tension for 48-hrs. Neutralization effect of 
IGF-IR or IR was measured in presence of 5 µg/mL of either neutralizing 
antibody in presence of 50 ng/mL of C) IGF-I or D) IGF-II in room air or low 
oxygen tension conditions for 24-hrs. The absorbance was read at 450 nm with a 
background reference of 650 nm. (Two-Way ANOVA, P<0.05, n=8, * = significant 
difference between room air and low oxygen tension, + = significant difference by 
IGF concentration in comparison with 0 ng/mL IGF). Low oxygen tension 
enhanced PMSC proliferation and increased the IGF effect in increasing PMSC 
proliferation. IGF-IR and IR are responsible for mediating IGF signaling to 
increase PMSC proliferation especially under low oxygen tension conditions. IGF 
enhanced proliferation in absence of exogenous IGF is mediated by endogenous 
IGF expression. 
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that the effect of IGF-I or -II was mediated additionally by another receptor. We 
tested whether IR was this receptor. In room air, IGF-I or IGF-II mediated 
proliferation was reduced by the IGF-IR neutralizing antibody and by IR 
neutralizing antibody (Fig. 3.6C and D). The reduction in proliferation was lower 
than without IGFs, suggesting that a portion of the proliferative response was due 
to endogenous IGF. On the other hand, low oxygen tension enhanced PMSC 
proliferation, and neutralizing the IGF-IR had a greater effect than IR 
neutralization (Fig. 3.6C). A combination of both receptor neutralizing antibodies 
completely abolished the IGF-I induced proliferation, suggesting a potential role 
for the hybrid receptor under this condition. Similarly in low oxygen tension, IGF-
II stimulation was more reduced by neutralizing the IR (Fig. 3.6D). The PMSC IR-
mediated proliferation was dependent on IGF stimulation as insulin stimulation 
alone did not increase proliferation regardless of oxygen tension (Fig. S3.7). 
Therefore, IGFs utilized both the IGF-IR and IR to promote PMSC proliferation, 
however, low oxygen tension can modulate IGF signaling response towards IGF-
IR for IGF-I signaling and the IR for IGF-II signaling. As mediators of IGF-IR/IR 
signaling, we checked the ERK1/2 and AKT phosphorylation levels. The 
presence of either IGF-IR or IR neutralizing antibody negated the effect of IGF-I 
by decreasing ERK1/2 phosphorylation (Fig. 3.7A). No major changes in p-
ERK1/2 levels were detected with IGF-II (Fig. 3.7B). AKT was more responsive 
to IGF stimulation, which was inhibited by IGF-IR and IR neutralizing antibodies. 
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FIGURE 3.7. IGF-mediated p-ERK1/2 and p-AKT signaling in PMSCs under 
low oxygen tension is partially regulated through the IGF-IR giving the IR a 
role in low oxygen tension. PMSC were stimulated in presence of 5 µg/mL of 
IG-IR or IR neutralizing antibodies in presence of A) and C) IGF-I (50 ng/mL) or 
B) and D) IGF-II (50 ng/mL) under room air or low oxygen for 24-hrs. From 
Immunoblots, detected levels of A) and B) p-ERK1/2 and C) and D) p-AKT were 
quantified and normalized to total kinase level followed by normalization to β-
actin used as a protein loading control. (Two-way ANOVA, p<0.05, n=3, † = 
significant difference by IGF concentration compared with 0 ng/mL, # = 
significant difference by the neutralization antibody effect compared with IGF 
alone). ERK1/2 phosphorylation was not decreased by antibody neutralization of 
IGF-IR or IR in PMSCs in presence of IGF-I. p-AKT was dependent on IGF-IR in 
room air but more dependent on the IR in low oxygen tension conditions.  
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As demonstrated earlier, increased p-AKT by IGF-I or -II is required for 
proliferation. IGF-IR neutralization in room air mediated a decrease only in the 
IGF-I induced p-AKT, whereas the IGF-II induced p-AKT was decreased in both 
oxygen tensions. IR neutralization had a more significant effect in low oxygen 
tension regardless of IGF-I or -II (Fig. 3.7 C and D). These results confirm that 
phosphorylation of AKT is more dependent on IGF signaling, than ERK1/2, in 
PMSCs and that low oxygen tension can differently mediate the IGF signaling 
through either the IGF-IR or the IR indicating an important role of the IR in low 
oxygen tension to mediate higher p-AKT levels and higher proliferation. 
 
3.4. DISCUSSION 
In this study, we have demonstrated that low oxygen tension can modulate 
PMSC response to IGF mediated signaling, proliferation and multipotency. We 
showed that low oxygen tension and not room air promoted the increased 
expression of IGF-II and less of IGF-I, and enhanced IGF-IR and IR expression. 
Moreover, low oxygen tension repressed the short-term stimulation of p-IGF-IRβ 
and p-AKT, while it potentiated p-ERK1/2 in the presence of IGF-I. However, 
after a prolonged stimulation with IGFs, low oxygen tension maintained a low 
level of p-ERK1/2 and mediated a dose dependent increase in p-AKT levels. 
Among the pluripotency transcription factors, we found that OCT4 is more stably 
maintained and is less altered by IGFs and oxygen tension, unlike NANOG and 
SOX2. PMSC proliferation was enhanced in low oxygen tension that potentiated 
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the effects of IGF-I and -II for higher proliferation level via the cooperative action 
of IGF-IR and IR.  
 
In the human placental mesodermal core, where placental mesenchymal stem 
cells (PMSCs) reside, IGF-II is more abundantly expressed as early as 6-weeks 
of gestation (first trimester) compared with IGF-I which begins after 12-weeks of 
gestation (second trimester onwards) (24). This suggests that IGF-II plays a 
major role in early placental development, possibly facilitating cytotrophoblast 
invasion and angiogenesis just preceding the formation of uterine circulation (25, 
26). Oxygen tension is an important microenvironmental factor in influencing 
growth factor expression and signaling. In particular, low oxygen tension can 
induce IGF-II gene expression in primary rat osteoblasts or human hepatoma 
cells in culture (27, 28). As previously shown, IGF-II is important to maintain 
embryonic stem cell identity as it is expressed by the surrounding differentiated 
fibroblast cells (8). In this study, we demonstrated a relationship between oxygen 
tension and the type of IGF ligand expressed by PMSCs (IGF-II in low oxygen 
and IGF-I in room air). Although, in early gestation placentae, low oxygen tension 
is known to have an abundant expression of IGF-II in vivo (24), PMSCs from 
different gestational stages still expressed high IGF-II when maintained under 
low oxygen tension conditions. Therefore, the increased expression of IGF-II can 
be solely due to low oxygen tension. Hence, maintaining PMSCs in a 
microenvironment that mimics their natural conditions can program PMSCs to 
adapt and behave as in vivo.   
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Among the pluripotency triad of transcription factors, OCT4 is regarded as the 
master regulator and gatekeeper of pluripotency to keep stem cells in 
undifferentiated state and prevent differentiation of hESCs into trophoblast-like 
cells (29-32). OCT4 is an indispensible transcription factor to induce pluripotency 
in iPSCs (18, 19, 32, 33). Also, OCT4 alone was sufficient to generate iPSCs, if 
neural progenitor cells, which already express endogenous SOX2, c-MYC and 
KLF4, were used for reprogramming (34). In our PMSCs, OCT4 protein levels 
were less susceptible to change, unlike NANOG and SOX2, in the presence of 
IGF-I or -II regardless of oxygen tension. This could be due to OCT4 being 
central for pluripotency and as a master regulator to keep stem cells in 
undifferentiated state, as it is tightly regulated (within 0.5-fold) to prevent 
differentiation or de-differentiation of hESCs (29, 30). In support of IGF and low 
oxygen tension maintenance of multipotency, we showed that low IGF 
concentrations could maintain higher levels of NANOG and SOX2.  
 
Activation of ERK1/2 and AKT signaling pathways is important in the 
maintenance of stem cell proliferation and multipotency. Interestingly, the role of 
ERK1/2 and/or AKT was dependent on oxygen tension. In differentiation studies, 
increased activation of ERK1/2 in low oxygen tension conditions promoted 
proliferation while AKT activation in room air promoted differentiation of 
myoblasts in culture (35). Inhibition studies done by others and us demonstrate 
that AKT activation is more important to maintain stem cell potency as measured 
by OCT4, NANOG and SOX2 levels (36). Also, the induction of PI3K/AKT 
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signaling pathway has been demonstrated to be central for pluripotency 
maintenance of hESCs by participating in promoting proliferation, preventing 
apoptosis and enhancing telomerase activity (37). The direct regulation of stem 
cell pluripotency by IGF signaling is not clear; however, it is proposed that IGF 
signaling can maintain pluripotency by phosphorylating the tumour suppressor 
p53, which acts as a negative regulator at OCT4 and NANOG promoters, and 
therefore IGF actions would disallow senescence and pluripotency gene 
repression (37). Apart from direct phosphorylation of p53, AKT can antagonize 
p53 by the direct phosphorylation of Mdm2 that in turn facilitates p53 
ubiquitination and degradation (38), hence decrease multipotency gene 
repression in stem cells. Therefore, a similar mechanism carried on by p-AKT 
can play a role in enhancing PMSC multipotency at the gene regulation level.  
 
In PMSCs, low oxygen tension modified IGF signaling starting at initial 
stimulation and also at prolonged stimulation. Low oxygen decreased the 
phosphorylation/activation of IGF-IRβ, ERK1/2 and AKT although an increased 
expression of the IGF-IR was evident. These changes can be due to changes in 
the phosphorylation mechanism or IGF binding sensitivity to IGF-IR and 
combination with IR, which is still unclear in low oxygen tension. However, 
ERK1/2 phosphorylation by IGF-I was transiently higher in low oxygen tension 
than in room air. It was shown that transient high p-ERK1/2 levels promote 
proliferation (39). A prolonged stimulation (48-hrs) with increasing concentration 
of IGF-I and -II changed the levels of ERK1/2 and AKT phosphorylation in 
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opposite directions, where the latter increased in a dose-dependent manner. In 
low oxygen tension, ERK1/2 was lowered even with IGF stimulation, possibly to 
maintain higher PMSC proliferation and inhibit differentiation. Therefore, low 
oxygen tension maybe required to decrease the continuous p-ERK1/2 level, as it 
is demonstrated that prolonged p-ERK1/2 levels are required for differentiation 
(39). In PMSCs, ERK1/2 is less dependent on IGF stimulation than AKT as 
shown by receptor activation. This was also shown from the receptor 
neutralization that IGF signaling is more critical for AKT than ERK1/2 
phosphorylation, which demonstrated the dependence of AKT on IGF 
stimulation, especially in presence of IGF-I, to mediate stem cell proliferation.  
 
Signaling through the IGF-IR is important to maintain stem cells in self-renewal 
state (8, 9). PMSC proliferation was dependent on the IGF-IR stimulation in room 
air and partially when in low oxygen tension. Both the IGF-IR and IR, which were 
upregulated in low oxygen tension, participated in mediating the IGF actions to 
induce PMSC proliferation in low oxygen tension. Interestingly, in neural 
progenitor stem cells, proliferation was dependent on IGF-II, which was mediated 
via the IGF-IR, while the IR-A had a more important role in maintaining self-
renewal than IGF-IR (40). Therefore, as PMSCs express both higher IGF-II and 
IR-A in low oxygen tension, it is possible that there is dependence on IGF-II/IR-A 
signaling to maintain PMSC multipotency and proliferation. IGF-II plays a major 
role in placental development, as the IGF-II knockout mice, but not the IGF-I or 
IGFIR knockout mice, caused a more significant growth reduction in mouse 
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placenta (10, 41). Therefore, our data suggests that human stem cells may also 
carry this dependence on IGF-II/IR when maintained in low oxygen tension 
conditions. Also, IGF signaling utilizes the IR in addition to IGF-IR, to maintain 
AKT phosphorylation, possibly due to the higher expression of the IR in low 
oxygen tension. We propose that the IR homodimer or the hybrid with the IGF-IR 
increases in low oxygen tension due to increased expression, and therefore can 
maintain stem cell character to in response of IGF-II signaling.  
 
Overall, placental stem cells are sensitive to their microenvironment with a higher 
dependence on low oxygen tension. We showed that culturing PMSCs under low 
oxygen tension modifies IGF signaling through the IGF-IR via ERK1/2 and AKT, 
suggesting that those two kinases participate in the regulation of stem cell fate. 
Also, we show that low oxygen tension can modify the stem cell dependence on 
IGF-IR by utilizing other signaling pathways, such as the IR, to maintain PMSC 
proliferation and multipotency. Thus, maintaining stem cells under low oxygen 
tension, similar to in vivo conditions, may be important in maintaining stem cell 
natural behaviour in preparation for regenerative therapy.  
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Appendix 2 
 
FIGURE S3.1. IGF ligand type expression in PMSCs is gestational age and 
oxygen tension dependent. PMSCs isolated from 11, 22, 38 weeks placentae 
were cultured for 48-hrs in either room-air or low-oxygen tension in serum and 
growth factor free conditions. By real-time PCR, expression level of IGF-I and -II 
mRNA were measured relative to RPL13a as an endogenous control. IGF-I 
levels were measured with increasing concentration of A) IGF-I or B) IGF-II. 
(Two-way ANOVA, p<0.05, n=3). IGF-I expression is elevated in room air at later 
gestation that is reduced further with PMSCs are maintained in low oxygen 
tension. IGF-II expression is higher at earlier gestation PMSCs and is enhanced 
by low oxygen.  
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Appendix 2 
 
FIGURE S3.2. PMSC stemness as measured by OCT4 is gestational age and 
oxygen tension dependent. PMSCs isolated from 11, 22, 38 weeks placentae 
were cultured for 48-hrs in either room-air or low-oxygen tension in 10% fetal 
bovine serum conditions. By immunoblotting, level of OCT4 protein levels were 
measured and normalized against β-Actin as an endogenous control. (Two-way 
ANOVA, p<0.05, n=3, * = significant difference between low oxygen tension and 
room air, # = significant difference by comparing gestational age). OCT4 from 
different gestations is maintained at higher levels by low oxygen tension.  
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FIGURE S3.3. IGF-IR and IR mRNA expression are decreased by IGF-I and -
II but elevated by low oxygen tension. PMSCs were cultured for 48-hrs in 
either room air or low oxygen tension in presence or absence of IGF-I or IGF-II 
(0, 10, 50, 100 ng/mL). By real-time PCR, expression level of  A) and B) IGF-IR 
or C) and D) IR-A or E) and F) IR-B mRNA were measured relative to RPL13a as 
an endogenous control in presence of IGF-I or IGF-II. (Two-way ANOVA, p<0.05, 
n=3, * = significant difference between room air and low oxygen tension, # = 
significant difference by different IGF concentrations).  
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FIGURE  S3.4. OCT4, NANOG and SOX2 expression is affected by IGF-I or -
II concentration depending on oxygen tension. PMSCs were cultured for 48-
hrs in either room air or low oxygen tension in presence or absence of IGF-I or 
IGF-II (0, 10, 50, 100 ng/mL). By real-time PCR, expression level of OCT4 or 
NANOG or SOX2 mRNA was measured relative to RPL13a as an endogenous 
control in presence of IGF-I or IGF-II. (Two-way ANOVA, p<0.05, n=3, *= 
significant difference between room air and low oxygen tension; a= significant 
difference of different IGF concentrations in room air, A= significant difference of 
different IGF concentrations in low oxygen tension). Low oxygen tension 
increased pluripotency associated gene expression where IGF treatment reduces 
them (more with IGF-I than IGF-II).  
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FIGURE S3.5. OCT4, NANOG and SOX2 expression is increased by IGF-I or 
-II oxygen tension. PMSCs (N=2) were cultured for 24, 48 or 72-hrs in either 
room air or low oxygen tension in presence or absence of IGF-I or IGF-II (100 
ng/mL). By real-time PCR, expression level of A) OCT4 or B) NANOG or C) 
SOX2 mRNA was measured relative to RPL13a as an endogenous control in 
presence of IGF-I or IGF-II. (Two-way ANOVA, p<0.05, n=3, *= significant 
difference between room air and low oxygen tension; a= significant difference of 
different IGF concentrations in room air, A= significant difference of different IGF 
concentrations in low oxygen tension).  
IGF-II (100 ng/mL)
Time (-hrs)O
C
T
4
m
R
N
A
 e
x
p
re
s
s
io
n
 (
-f
o
ld
)
24 48 72
0
1
2
3
4
5
Room-air
Low-oxygen
*
*
a
a
a
A
A
B
IGF-Free (0 ng/mL)
Time (-hrs)O
C
T
4
m
R
N
A
 e
x
p
re
s
s
io
n
 (
-f
o
ld
)
24 48 72
0
1
2
3
4
5
* *
A
B
a a
b
B
IGF-I (100 ng/mL)
Time (-hrs)O
C
T
4
m
R
N
A
 e
x
p
re
s
s
io
n
 (
-f
o
ld
)
24 48 72
0
1
2
3
4
5
*
*
a
a a
A
A
B
IGF-Free (0 ng/mL)
24 48 72
0
1
2
3
4
5
Time (-hrs)N
A
N
O
G
m
R
N
A
 e
x
p
re
s
s
io
n
 (
-f
o
ld
)
* *
a a
aA
A
B
IGF-I (100 ng/mL)
24 48 72
0
1
2
3
4
5
Time (-hrs)N
A
N
O
G
m
R
N
A
 e
x
p
re
s
s
io
n
 (
-f
o
ld
)
*
*
a
a a
A
A
B
IGF-II (100 ng/mL)
24 48 72
0
1
2
3
4
5
Time (-hrs)N
A
N
O
G
m
R
N
A
 e
x
p
re
s
s
io
n
 (
-f
o
ld
)
*
*
a
a
b
a
B
C
IGF-Free (0 ng/mL)
24 48 72
0
1
2
3
4
5
Time (-hrs)S
O
X
2
m
R
N
A
 e
x
p
re
s
s
io
n
 (
-f
o
ld
)
*
a a a
A A
A
IGF-I (100 ng/mL)
24 48 72
0
1
2
3
4
5
Time (-hrs)S
O
X
2
m
R
N
A
 e
x
p
re
s
s
io
n
 (
-f
o
ld
)
**
a
a b
A A
B
IGF-II (100 ng/mL)
24 48 72
0
1
2
3
4
5
7
Time (-hrs)S
O
X
2
m
R
N
A
 e
x
p
re
s
s
io
n
 (
-f
o
ld
) *
a
a
a
A
A
B
A
B
C
134 
 
 
  
 
Appendix 2 
FIGURE S3.6. IGF-mediated PMSC proliferation under low oxygen tension 
is partially regulated through the IGF-IR. PMSC proliferation was assessed 
using the WST-1 colorimetric proliferation assay in presence of increasing 
concentration of 1H7 antibody (0, 2.5, 5, 10 , 25 µg/mL) in presence or absence 
of A) IGF-I (50ng/mL) or B) IGF-II (50ng/mL) under room air or low oxygen for 
24-hrs. The absorbance was read at 450 nm with a background reference of 650 
nm, (Two-Way ANOVA, P<0.05, n=8, * = significant difference between room air 
and low oxygen tension; X = significant difference of IGF-I or IGF-II, # = 
significant difference of of neutralizing antibody compared with IGF effect).  
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FIGURE S3.7. PMSC proliferation is not responsive to insulin stimulation 
even in low oxygen tension. PMSC proliferation was assessed using the WST-
1 colorimetric proliferation assay in presence of increasing concentration of 
insulin (0, 10, 100, 1,000, 10,000 ng/mL) under room air or low oxygen for 48-
hrs. The absorbance was read at 450 nm with a background reference of 650 
nm. (Two-Way ANOVA, P<0.05, n=8, *= significant difference between room air 
and low oxygen tension). Low oxygen tension enhanced PMSC proliferation 
without an effect of increasing concentration of insulin.  
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CHAPTER FOUR 
Insulin-like Growth Factor and Low Oxygen Tension Regulate Osteogenic 
Differentiation of Placental Mesenchymal Stem Cell  
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4.1. INTRODUCTION 
Mesenchymal stem cells (MSCs) are found in many adult tissues and are 
responsible for tissue repair and homeostasis (1). Unlike ESCs, MSCs are less 
tumorigenic and have a more restricted mesendodermal lineage-specific 
differentiation (2) towards myocytes, osteoblasts, chondrocytes, adipocytes, 
stromal fibroblasts, and endothelial cells (1, 3, 4). In addition, MSCs have been 
demonstrated to form neuroblasts in vitro, and neuron-like cells bearing axons 
and dendrites in vivo (5). Also, MSCs can modulate the immune response and 
were successfully used in graft vs. host disease resistant patients (6). Therefore, 
MSCs are increasing in promise for stem cell-based therapies to treat many adult 
and paediatric diseases, such as sickle cell disease (7), rheumatic diseases (8), 
lymphoma (9), and heart failure (10).  
 
In bone, MSC transplantation has been utilized to correct bone malformation and 
injury. Osteogenesis imperfecta (OI) is a severe pediatric genetic disorder of 
mesenchymal cells with a deficit for type-I collagen synthesis, which is critical for 
matrix deposition and mineralization in bone (11). There is no treatment for OI, 
however, an allogeneic bone-marrow transplantation was shown to successfully 
accelerate linear growth and increase total body bone mineral density in children 
with OI (11). Also in bone injury, MSCs have the potential to treat the more 
severe nonunion bone fractures and accelerate recovery of delayed union. In a 
mouse model, bone-marrow MSCs administered by systemic infusion 
138 
 
 
  
successfully homed to the fracture site and accelerated the initiation of a callus 
and improved the cartilage and bone content (12). Therefore, the use of MSCs 
for the treatment of bone diseases and injury is a promising regenerative therapy.  
 
Although bone-marrow MSCs have been used for stem cell therapy (13, 14), the 
challenge has been their availability. Placental MSCs (PMSCs) are abundant, 
readily available and do not require invasive isolation techniques (15). PMSCs 
are isolated from different parts of the placenta (amnion, chorion and umbilical 
cord) and have a higher proliferation capacity than bone-marrow MSCs (15). In 
culture, MSCs are dependent on their surrounding microenvironment for 
maintaining stem cell identity, and they differentiate by the signaling by several 
growth promoting factors and the use of lineage specific cell culture conditions 
(16, 17). In this microenvironment, several clues regulate stem cell differentiation 
by a tight transcriptional network of losing multipotency and initiating linage-
specific differentiation. In osteoblast differentiation, RUNX2 is known as a 
lineage-specific regulator transcription factor that upregulates transcription of 
genes required for bone matrix deposition and mineralization including 
osteopontin (OPN), osteocalcin, type-I collagen, alkaline phosphatase, etc. (18-
21). In this process, RUNX2 is strongly detected in preosteoblasts, immature 
osteoblasts, and early osteoblasts. However, its continued expression at later 
stages of mature osteoblast differentiation inhibits complete differentiation (20, 
22). 
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In the stem cell microenvironment, MSCs reside in low oxygen tension, which 
promotes stem cell proliferation, self-renewal and multipotency (23). However, 
low oxygen tension can severely inhibit osteoblast differentiation in vitro (24), 
while re-exposure to room air restores differentiation and may potentiate 
osteogenic differentiation (25, 26). In this process, the hypoxia inducible factor 
(HIF) system is responsible for downregulating the expression of osteoblast 
commitment genes, such as RUNX2 (27, 28), and a complete differentiation is 
obscured due to inhibition of expression of downstream genes responsible for 
mineralization and matrix formation (27). However, in vivo, inhibiting cellular 
responses in low oxygen tension by HIF1α knockout decreases trabecular bone 
volume, reduces bone formation rate, alters cortical bone architecture and 
reduces proliferation of osteoblasts during long bone development (29). In 
contrast, an over-expression of HIF-1α in osteoblasts leads to the development 
of extremely dense and heavily vascularized long bones (30). Therefore, the 
regulation of gene expression by low oxygen tension is required for healthy 
development of bone in vivo at least at the initial stages as confirmed by 
preconditioning experiments. In this context, long-term exposure to low oxygen 
tension is inhibitory to stem cell differentiation, although a short term exposure 
can play a role in directing stem cell fate towards osteogenic differentiation (25).   
 
In addition to oxygen tension, stem cell differentiation conditions can be defined 
by soluble factors, small molecules, hormones, and growth factors. The insulin-
like growth factors (IGFs, IGF-I and IGF-II) can promote and stimulate stem cell 
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differentiation towards hepatic (31), endothelial (32), adipogenic (33) and 
osteogenic (34, 35) lineages. In osteogenic tissues, the expression of IGF-I, IGF-
II and their receptor IGF-IR, has a strong association with osteogenesis and are 
abundantly expressed specifically in mature osteoblasts and osteoclasts by 
autocrine/endocrine mechanisms (36). The IGF-I and IGF-IR null mice show 
short bone, low bone mineral density, and delayed calcification, whereas, IGF-II 
null mice show no major skeletal defects (37). IGFs have no effect on osteoblast 
differentiation commitment (no change in RUNX2 expression), but enhance the 
differentiation function by promoting growth, inhibiting apoptosis and upregulating 
matrix maturation (increased type-I collagen) and mineralization (38). Also, in 
vivo, the use of MSCs that overexpress IGF-I improves fracture healing by 
accelerating bone cell differentiation which is dependent on IRS1-PI3K pathway 
in mediating the IGF-I dependent osteogenic actions via paracrine and autocrine 
functions (39).   
 
IGFs and low oxygen tension are endogenous components of the osteogenic 
microenvironment, which are shown to affect later stages of osteogenic 
differentiation during the mineralization period of MSC differentiation (27, 38). 
However, the combined effect of these two microenvironmental factors on the 
commitment and early differentiation stages has not been investigated. In this 
study, we used MSCs isolated from the chorionic villi of the human placenta 
(PMSCs) to study the role of IGF-I and IGF-II signaling in combination of low 
oxygen tension in osteogenic differentiation. We show that low oxygen tension 
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inhibits the differentiation of PMSCs towards the osteogenic lineage and IGF-I 
enhances differentiation via specific signaling pathways. 
 
4.2. MATERIAL AND METHODS 
4.2.1. PMSC Isolation 
PMSCs were isolated from early gestation (10-13 weeks) human placentae. After 
informed consent, preterm placentae were collected from patients who 
underwent therapeutic pregnancy termination. Immediately after surgery, 
placentae were dissected under sterile conditions and small pieces of chorionic 
villi were collected. Tissue samples were minced mechanically and subjected to 
a process consisting of two steps of enzymatic digestion with (1) collagenase 
IV/hyaluronidase, and (2) DNase I followed by (3) trypsin/EDTA. Each enzymatic 
step was performed for 20 min at 37ºC, followed by 10 min wash at 4ºC in a 
solution of PBS supplemented with 10% fetal bovine serum (FBS) (Gibco, 
Mississauga, ON, CAN). Cells released during digestion were passed through a 
tissue mesh (45 μm) to obtain a single cell suspension. Next, cells were 
separated on a Percoll (Sigma) discontinuous gradient according to a modified 
protocol by Worton et al. for hematopoietic stem cell isolation (40) and then 
seeded in DMEM/F12 media (Gibco, Mississauga, ON, CAN) supplemented with 
10% FBS and antibiotic-antimycotic solution. After 4 days, media was changed 
and non-adherent cells were washed with media to leave behind adherent 
PMSCs able to form colonies.  
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4.2.2. Cell Culture and Incubation in Low Oxygen Tension 
For each experiment, two preterm PMSC cell populations were used in triplicate.  
Cells were cultured and maintained using DMEM/F12 media supplemented with 
10% ES-FBS and FGF-2 (100 ng/mL) (Gibco, Mississauga, ON, CAN). Before 
treatments, cells were cultured in DMEM/F12 supplemented 10% FBS only. 
Upon treatment, PMSCs were switched to fresh media containing IGF-I or IGF-II 
(0 – 300 ng/mL). For IGF-IR neutralizing, cells were grown in serum-free media 
for 24-hrs and then switched for 2-hrs in serum-free media with 1.33x final 
concentration of 1H7 Ab (in 75% final volume). Secondly, Serum-free media 
containing 4x final concentration of IGF-I or -II (in 25% final volume) was added 
and incubated for the rest of 24-hrs. Cell cultures were then placed in either a 5% 
CO2 incubator or a hypoxia chamber, which was filled with a mix of (1% O2, 5% 
CO2, Balanced N2) (BOC Canada Ltd, Toronto, ON, CAN) for 15 min to ensure 
saturation using a Hudson 5590 Oxygen Monitor (Hudson, Ventronics Division, 
Temecula, CA, USA). Thereafter, the chamber was placed in a tissue-culture 
incubator at 37o C.  
 
4.2.3. Osteogenic Differentiation 
PMSCs were plated at 70% confluency in non-differentiation conditions (15% 
FBS/DMEMF12) or in presence of osteogenic stimulatory conditions (15% 
osteogenic differentiation FBS, 10-8 M Dexamethasone, 50µg/mL Ascorbic acid, 
and 3.5 mM β-Glycerophosphate) (Stem Cell Technologies, Vancouver, BC, 
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CAN). With IGF-I or -II treatments, 100 ng/mL of either IGF was added 
continuously to a reduced FBS level of 2% instead of 15% in either media. 
Relative effect of different IGF and oxygen tension treatments on calcium 
deposits was compared using alizarin red and alkaline phosphatase staining. The 
signaling of MEK/ERK pathway or the PI3K/AKT pathways was inhibited by the 
continuous presence of U0126 (5 µM) or LY294002 (10 µM), respectively. To 
assess these morphological changes of differentiated vs. non-differentiated, cells 
were cultured for 14-days and then fixed with 4% formaldehyde for 30 min at RT. 
Then cells were either stained with 1% Alizarin Red solution for 10 min at RT, or 
with NBT/BCIP reagents as per manufacturer’s protocol. Both staining were then 
solubilized with 10% cetylpyridinium chloride in 10mM sodium phosphate buffer 
pH 7.0 as previously described (35). The absorbance of 200 µL solubilized 
staining was read at λ=570nm using a plate reader. The absorbance was then 
normalized to total protein content per well in micro-grams. 
 
4.2.4. Immunoblotting 
Cell lysates were prepared using 1x cell lysis buffer for phospho-proteins 
according to manufacturer protocol (#9803, Cell Signaling Technologies, 
Burlington, ON, CAN). Protein samples (10-20 μg) from each cell lysate were 
resolved by 10% SDS-PAGE, and then transferred onto PVDF membranes 
(Millipore, Bedford, MA). The membranes were blocked with 5% bovine-serum-
albumin or in 5% non-fat-dry milk in 1x TBS (Tris-buffered saline) for 1 hr at room 
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temperature. Blots were then washed in 1x TBS 0.1% Tween 20 (TBS-T) (3x for 
5 min) followed by incubation at 4oC overnight with primary antibodies as per 
manufacturer’s protocols. Blots then were washed using TBS-T (3x for 10 min) 
and were incubated with the corresponding secondary HRP-labelled antibody for 
1 hr at RT. Immunocomplexes were detected by ECL and documented using 
VersaDOCTM Imaging System (Bio-Rad). 
 
4.2.5. Antibodies 
To investigate the IGF-I activated signaling molecules in placental MSCs, we 
used the following antibodies: phospho-p44/42 MAPK (#4377), p44/42 MAPK 
(#9102) phospho-AKT (Ser473, #4051), AKT (#9272) from (Cell Signaling 
Technologies, Burlington, ON, CAN) and IGF-IRα (N-20, sc-712) and IR- α (N-
20, sc-710) (Santa Cruz Biotech., Santa Cruz, CA, USA). For multipotency 
markers, we used OCT3/4 antibody (N-19, sc-8628) (Santa Cruz Biotech., Santa 
Cruz, CA, USA) and SOX-2 (2683-1) (Epitomics, Burlington, ON, CAN). For the 
osteogenic differentiation markers we used RUNX2 (#8486) from (Cell Signaling 
Technologies, Burlington, ON, CAN) and OPN (K-20, sc-1059) from (Santa Cruz 
Biotech., Santa Cruz, CA, USA). For loading control, we used pan-Actin Ab-5 
(#MS-1295) (Thermo Fisher Scientific, Fremont, CA). The secondary antibodies 
used for immunoblotting were goat anti-rabbit (#170-6515), anti-mouse (#170-
6516) HRP conjugated antibodies (BioRad laboratories, Hercules, CA) or donkey 
anti-goat antibody (sc-2020) Santa Cruz Biotech., Santa Cruz, CA, USA).  
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4.2.6. Statistical Analysis 
All experiments were run in triplicates from three independent experiments each; 
whenever possible three or more PMSC primary lines were used from preterm 
placentae. All graphs and analyses were generated using GraphPad Prism 
Software 5.0 (GraphPad Software, San Diego, CA). A Two-way ANOVA with 
Bonferroni post hoc test was used for the PMSC WST1 proliferation assay and 
densitometry quantifications. Data are expressed as mean ± standard error of the 
mean (SEM); values were considered significant when p<0.05. 
 
4.3. RESULTS 
4.3.1. Effect of low oxygen tension on PMSC osteogenic differentiation 
We selected to use preterm PMSCs (11 – 13 wks gestation) to be studied for 
differentiation into osteogenic lineage. The progressive morphological changes 
over 14 days were greater in room air when maintained in osteogenic 
differentiation conditions. Low oxygen tension inhibited osteogenic differentiation 
over the same time period (Fig. 4.1A), and enhanced cell proliferation compared 
with room air (Fig. S4.1). Alizarin red staining showed that PMSCs could 
spontaneously differentiate into an osteogenic-like cells in room air beginning at 
day 3, and was limited by low oxygen tension (Fig. 4.1B). Therefore, low oxygen 
tension oxygen tension (Fig. 4.1B). 
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FIGURE 4.1. PMSC differentiation under low oxygen tension. PMSCs were 
cultured for 14-days in non-differentiation or osteogenic differentiation conditions 
containing 15% FBS in room air (20% O2) or low oxygen levels (1% O2). 
Treatments were stopped after (1, 3, 7, 10, 14 days) for alizarin red staining to 
confirm (A) PMSC differentiation morphology and quantified in (B). (Two-Way 
ANOVA, P<0.05, n=4, * = significant difference between room air and low oxygen 
tension; a= significant difference of differentiation condition in room air, A= 
significant difference of differentiation condition in low oxygen tension). 
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Therefore, low oxygen tension inhibited differ PMSC spontaneous differentiation 
in growth conditions and osteogenic differentiation under differentiation 
conditions. 
 
To monitor PMSC stemness during differentiation, stem cell markers OCT4 and 
SOX2 were determined, in addition to the osteogenic differentiation and 
commitment transcription factor RUNX2. During osteogenic differentiation, OCT4 
and SOX2 levels were consistently higher in low oxygen tension compared to 
room air (Fig. 4.2A and B). OCT4 levels were unchanged upon differentiation in 
either oxygen tension, whereas, SOX2 levels were moderately decreased. At 14 
days, RUNX2 levels were increased upon differentiation in room air but were 
lower when maintained in low oxygen tension (Fig. 4.2C). Therefore, low oxygen 
tension reduced PMSC differentiation by maintaining higher level of pluripotency 
genes (higher OCT4 and SOX2), and reducing differentiation commitment 
towards the osteogenic lineage (lower RUNX2).  
 
4.3.2. Low oxygen tension preconditioning enhances PMSC osteogenic 
differentiation 
We evaluated whether preconditioning PMSCs in low oxygen tension, which 
maintain multipotency, can enhance differentiation when exposed to  
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FIGURE 4.2. Effect of low oxygen on PMSC osteogenic differentiation and 
stemness. PMSCs were cultured for 14-days in non-differentiation or osteogenic 
differentiation conditions containing 15% FBS in room air or low oxygen levels. 
Treatments were stopped after 14 days. Protein levels for A) OCT4, B) SOX2, 
and C) RUNX2 were quantified from Immunoblots. Quantification levels shown 
were normalized to β-Actin, a protein loading control. (Two-Way ANOVA, 
P<0.05, n=3, * = significant difference between room air and low oxygen tension, 
# = significant effect by differentiation condition). 
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FIGURE 4.3. Effect of low oxygen tension preconditioning on PMSC 
osteogenic differentiation. PMSCs were cultured in non-differentiation or 
osteogenic differentiation conditions containing 15% FBS in room air or low 
oxygen levels for 14-days as in Fig. 4.1. For preconditioning, PMSCs were 
cultured for 7 days in low oxygen and followed by 7 days in room air (shown in 
the third panel). Alizarin red or alkaline phosphatase staining was used to detect 
calcium deposition and enzyme expression changes as shown morphologically in 
(A) and quantified in (B). (Two-Way ANOVA, P<0.05, n=4, a = significant 
difference by oxygen tension in non-differentiation conditions, A = significant 
difference by oxygen tension in differentiation conditions). 
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FIGURE 4.4. Effect of low oxygen tension preconditioning on PMSC 
stemness and osteogenic differentiation. Similarly as in Fig. 4.3, PMSCs were 
cultured for 14-days in non-differentiation or osteogenic differentiation conditions 
containing 15% FBS in room air or low oxygen levels. For preconditioning, 
PMSCs were cultured in low oxygen tension for 7 days followed by 7 days in 
room air. Immunoblots were used to detect levels of (A) OCT4, (B) SOX2, and 
(C) RUNX2 levels. Quantification levels shown were normalized to β-Actin, a 
protein loading control. (Two-Way ANOVA, P<0.05, n=3, * = significant difference 
between differentiation and non-differentiation conditions, a = significant 
difference by oxygen tension in non-differentiation conditions, A = significant 
difference by oxygen tension in differentiation conditions). 
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room air. This scenario mimics the in vivo differentiation condition. Alizarin red 
staining was returned to same levels as room air by exposure to room air for the 
final 7 days of the differentiation course (Fig. 4.3A and 4.3B-left). This was also 
confirmed by alkaline phosphatase staining (Fig. 4.3B-right). At the molecular 
level, preconditioning in low oxygen tension maintained higher levels of OCT4 
and SOX2 which were reduced upon differentiation in room air (Fig. 4.4A and B). 
RUNX2 levels were also increased to room air levels upon re-exposure to room 
air (Fig. 4.4C). This shows that low oxygen tension programs PMSCs and 
enhance/potentiate osteogenic differentiation when exposed to higher oxygen 
tension in room air, which is required for completing osteogenic differentiation.  
 
4.3.3. Effect of insulin-like growth factors on PMSC osteogenic 
differentiation in low oxygen tension 
The additional role of IGFs in mediating the differentiation process in low oxygen 
tension was investigated by adding IGF-I or -II for 14 days under continuous 
room air or low oxygen tension conditions (Fig. 4.5). There was no increase in 
alizarin red staining or increase in spontaneous differentiation in either room air 
or low oxygen tension in absence of IGFs (Fig. 4.5A). However, IGF-I was able to 
increase earlier spontaneous differentiation in room air. In differentiation 
conditions, both IGF-I and IGF-II enhanced osteogenic differentiation in room air  
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FIGURE 4.5. PMSC Differentiation is regulated by IGFs. PMSCs were 
cultured in non-differentiation or osteogenic differentiation conditions containing 
2% FBS and either 100 ng/mL of IGF-I or IGF-II, in room air or low oxygen levels. 
Treatments were stopped after 3, 7, and 14 days for (A-B) alizarin red staining to 
confirm PMSC differentiation morphology changes into osteogenic lineage and 
quantified in (C-F). (Two-Way ANOVA, P<0.05, n=4, X = significant difference 
between different days of the same IGF condition, # = significant difference by 
IGF at the same day compared with 0 ng/mL IGF). 
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as confirmed by the increase in alizarin red staining (Fig. 4.5D). In low oxygen 
tension, IGF-I and IGF-II enhanced cell condensation (Fig. 4.5B), but did not 
increase alizarin red staining (Fig. 4.5F). Interestingly, IGF-I or IGF-II in room air 
enhanced alizarin red staining intensity starting at day 3 and reached maximum 
by day 7, whereas control (IGF free conditions) required 14 days to reach the 
same level (Fig. 4.5D). Therefore, IGF-I and -II enhance differentiation at an 
earlier time point in room air. 
 
At the molecular level, low oxygen tension inhibited differentiation as shown by 
OCT4 and SOX2 levels (Fig. 4.6A and B). SOX2 was reduced upon 
differentiation in room air only (Fig. 4.6A and B). The osteogenic initiation 
transcription factor RUNX2 was increased in differentiation in room air but not in 
low oxygen tension (Fig. 4.6A and B). OPN, used as a later marker of 
differentiation for matrix deposition, increased by day 14 only in room air in 
differentiation conditions (Fig. 4.6A and B). Therefore, differentiation in room air 
is required to reduce SOX2, and increase RUNX2 and OPN upon PMSC 
differentiation.  
 
In osteogenic differentiation, IGFs increased OCT4 levels at day 3 and day 7 in 
room air with no effect was observed at day 14. When differentiation occurred in 
low oxygen tension, IGFs induced higher levels of OCT4 at all time points (Fig.  
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FIGURE 4.6. PMSC differentiation is inhibited by low oxygen tension. 
Similarly to Fig. 4.5, PMSCs were cultured for 14-days in non-differentiation or 
osteogenic differentiation conditions containing 2% FBS reduced from 15% FBS 
as shown in Fig. 4.2, in room air or low oxygen levels. Treatments were stopped 
after 3, 7, and 14 days. Immunoblotting was used to detect levels of (A) OCT4, 
SOX2, RUNX2, and OPN over the three stop days. (B) Quantification levels are 
shown from day 14 time point for OCT4, SOX2, RUNX2 and OPN, normalized to 
β-Actin, a protein loading control. (Two-Way ANOVA, P<0.05, n=3, * = significant 
difference between room air and low oxygen tension, X = significant difference by 
differentiation condition). 
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4.7A). Under room air, SOX2 was increased by IGF-I treatment at day 3 but 
showed no significant changes following IGF treatment at day 7 or day 14. Under 
low oxygen tension, SOX2 was reduced by IGF-I at day 3 and by IGF-II at day 3 
and 7 but with no effect at day 14 (Fig. 4.7B). RUNX2 was increased by IGF-I 
and IGF-II at the initial stages of differentiation (day 3), and maintained at day 14 
(Fig. 4.7C), and low oxygen tension negated this effect. Changes in OPN were 
similar to RUNX2 (Fig. 4.7D). Therefore, IGF-I can enhance the PMSC 
differentiation towards the osteogenic lineage, more than IGF-II. This 
differentiation effect was accelerated by inducing an earlier increase in 
osteogenic differentiation markers (RUNX2 and OPN) with a reduction in 
pluripotency markers (SOX2).   
 
4.3.4. Effect of insulin-like growth factors on the role of IGF-IR and IR on 
PMSC osteogenic differentiation in low oxygen tension 
IGF-I and IGF-II signaling is mediated via the interaction with the IGF-IR or the IR 
to promote proliferation and differentiation. In room air, IR is increased in 
differentiating PMSCs and upregulated by IGF-I; IGF-IR was not affected by IGFs 
(Fig. 4.8A and C). In low oxygen tension, the IGF-IR was increased by 
differentiation conditions and reduced by IGFs. No change of the IR was 
observed in presence of IGFs in low oxygen tension (Fig. 4.8A and B).  
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FIGURE 4.7. PMSC multipotency and differentiation is regulated under low 
oxygen tension by IGFs. Similarly to Fig. 4.6, PMSCs were cultured for 14-days 
in non-differentiation or osteogenic differentiation conditions containing 2% FBS 
containing 100 ng/mL of IGF-I or IGF-II in room air or low oxygen levels. 
Treatments were stopped after 3, 7, and 14 days. Immunoblotting was used to 
detect levels of (A) OCT4, (B) SOX2, (C) RUNX2, and (D) OPN changes induced 
by IGFs over the three stop days. Quantification levels were normalized to β-
ACTIN, a protein loading control. (Two-Way ANOVA, P<0.05, n=3, * = significant 
difference by time in no IGF conditions, X = significant difference by IGF-I or IGF-
II in differentiation conditions). 
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To specify the role of downstream signaling of ERK1/2 and AKT in mediating 
PMSC differentiation, U0126 and LY294002 were used to inhibit the signaling via 
the MEK1/2 and PI3K, respectively. In non-differentiation conditions, the addition 
of U0126 and LY294002 every 48 hours reduced phosphorylation of ERK1/2 
(Fig. S4.2A) and AKT (Fig. S4.2B), respectively. After 14 days, the alizarin red 
staining was reduced by LY294002 more than with U0126 (Fig. 4.9A and B). 
Also, after 14 days of differentiation, LY294002 increased p-ERK1/2 levels in low 
oxygen tension (Fig. S4.3A). AKT phosphorylation was inhibited by LY294002, 
and even more in differentiation condition in low oxygen tension conditions (Fig. 
S4.3B). Incubation with LY294002 or U0126 for 14 days did not change PMSC 
viability (Fig. S4.4); however, differentiation was inhibited (Fig. 10). U0126 
increased RUNX2 under differentiation conditions in low oxygen tension, while 
OPN was decreased in room air (Fig. 10C and D). LY294002 reduced OCT4, 
SOX2, RUNX2 and OPN in differentiation conditions but more in low oxygen 
tension (Fig. 10A - D). Therefore, PI3K signaling is required for PMSCs to 
maintain multipotency in non-differentiation condition and to mediate 
differentiation in osteogenic differentiation conditions. MEK1/2 inhibited RUNX2 
levels in low oxygen tension. Therefore, both signaling pathways are important 
for PMSC differentiation depending on oxygen tension, with PI3K signaling being 
of greater importance to mediate PMSC differentiation towards the osteogenic 
lineage.  
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FIGURE 4.8. IGF-IR and IR levels in differentiating PMSCS is regulated by 
oxygen tension and IGFs. PMSCs were cultured for 14-days in non-
differentiation or osteogenic differentiation conditions containing 2% FBS with 
100 ng/mL of IGF-I or IGF-II in room air or low oxygen levels. Treatments were 
stopped after 3, 7, and 14 days. Immunoblots were used to detect levels of (A) 
IGF-IR and IR in absence of IGFs over time. Quantification of IGF effects on (B) 
IGF-IR and (C) IR over the three days is shown. Levels were normalized to β-
ACctin, a protein loading control. (Two-Way ANOVA, P<0.05, n=3, X = significant 
difference by time in no IGF conditions, # = significant difference by IGF-I or IGF-
II in differentiation conditions). 
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FIGURE 4.9. PMSC differentiation is mediated via MEK1/2 and PI3K 
signaling under low oxygen tension. PMSCs were cultured for 14-days in non-
differentiation or osteogenic differentiation conditions containing 2% FBS in room 
air or low oxygen levels. During the 14 days, a continuous exposure to (5 μM) 
U0126 or (10 μM) LY294002 containing media was changed every 48-hrs. 
Treatments were stopped at 14 days and stained with alizarin red to confirm (A) 
PMSC differentiation morphology changes into osteogenic lineage and quantified 
in (B). (Two-Way ANOVA, P<0.05, n=4, * = significant difference between room 
air and low oxygen tension, X = significant difference between differentiation and 
non-differentiation conditions, # = significant difference by inhibitor as compared 
to DMSO). 
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4.4. DISCUSSION  
For the successful use of stem cells for cell based therapies, optimization of stem 
cell survival and potency in vitro and preventing cell death in vivo after injection 
are major considerations (41). In addition, differentiation towards a progenitor cell 
population without residual undifferentiated cells is required (42). In this study, 
we used low oxygen tension and IGFs to manipulate the PMSC 
microenvironment to understand their interactions to improve PMSC 
differentiation towards the osteogenic lineage. We found that low oxygen tension 
delayed or inhibited PMSC differentiation and reduced the effects of IGF-induced 
earlier osteogenic differentiation. In vitro, osteogenic differentiation follows a 
three phase process: a differentiation phase (days 0 – 5), a matrix formation 
phase (days 5 – 12) and a mineralization phase (days 12 – 19) (27). In this study, 
we investigated the role of IGFs in combination of low oxygen tension in the 
commitment and matrix formation phases of PMSC differentiation (days 0 – 14). 
We demonstrated that RUNX2 is expressed in early differentiation where low 
oxygen tension impeded its increased levels. OPN, as a late osteogenic 
differentiation marker, was also reduced by low oxygen tension. IGFs enhanced 
PMSC differentiation only in room air (a greater effect of IGF-I than IGF-II) where 
low oxygen tension abolished this process. Similarly, this has been shown 
previously that IGF-I increases the early differentiation marker RUNX2, and the 
late markers Type-I collagen and alkaline phosphatase (35).  
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FIGURE 4.10. PMSC multipotency and differentiation is regulated by 
MEK1/2 and PI3K and is dependent on low oxygen tension. PMSCs were 
cultured for 14-days in non-differentiation or osteogenic differentiation conditions 
containing 2% FBS in room air or low oxygen levels. During the 14 days, a 
continuous exposure to (5 μM) U0126 or (10 μM) LY294002 containing media 
was changed every 48-hrs. Treatments were stopped at 14 days and 
immunoblots were used to detect levels of (A) OCT4, (B) SOX2, (C) RUNX2, and 
(D) OPN changes induced by signaling inhibition. Quantification levels were 
normalized to β-Actin, a protein loading control. (Two-Way ANOVA, P<0.05, n=3, 
* = significant difference between room air and low oxygen tension, X = 
significant difference between differentiation and non-differentiation conditions, # 
= significant difference by inhibitor as compared to DMSO).  
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The role of the transcriptional network of OCT4, SOX2 and NANOG in 
maintaining pluripotency and suppressing differentiation was elucidated recently 
in mouse and human embryonic stem cells. In mESCs, mesodermal lineage 
specification is determined by OCT4 and SOX2 expression levels: a balanced 
expression maintains pluripotency, upregulation of OCT4 relative to SOX2 
induces mesendodermal lineage specification, and downregulation of OCT4 
relative to SOX2 induces neural ectodermal lineage specification (43, 44). In 
human ESCs, OCT4 maintains an embryonic stem cells state and represses 
extraembryonic differentiation, while SOX2 is required to suppress the 
differentiation towards the mesendodermal and NANOG suppresses the 
ectodermal linage (45). In PMSCs, osteogenic differentiation increased the levels 
of OCT4 and decreased the levels of SOX2, as would be expected in a 
mesodermal lineage differentiation. Low oxygen tension increased both OCT4 
and SOX2 levels, thereby maintaining a more multipotent state even under 
differentiation conditions (46). Recently, OCT4 was shown to be required for in 
vivo and in vitro differentiation processes as it participates in the downregulation 
of the pluripotency program and that OCT4 deficient cells are unable to 
differentiate (47). In this study, we observed that differentiating PMSCs increased 
OCT4 levels prior to differentiation.  
 
Oxygen tension is increasingly recognized as an important factor of the stem cell 
niche for proliferation, migration, metabolism and differentiation. In bone 
fractures, oxygen level can go as low as 0.1% (~0.76 mm Hg) (27, 48). Also, 
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oxygen tension at the fracture site of the femoral head can be as low as 17.3-
19.9 mm Hg, and even lower, at 1 cm away from fracture site (12.5-12.8 mm Hg) 
(49). Therefore, preconditioning of PMSCs in low oxygen tension, before 
application into bone fracture, can improve survival of PMSCs and therefore 
healing of the tissue in the injury site of scarce oxygen tension just as 
hypothesized previously (25). This was confirmed as reported previously that low 
oxygen tension preconditioning of MSCs enhances successful engraftment to 
infarcted myocardium, reduced cell death and increased angiogenesis (50).  
 
The inhibition of differentiation by low oxygen tension could be due to the 
metabolic switch requirement for osteogenic differentiation, which relies on the 
upregulation of mitochondrial function and aerobic respiration seen in room air 
(28). Low oxygen tension can hinder this process by reducing energy production 
(ATP) by glycolysis alone, which is not sufficient for the high energy demanding 
differentiation processes required for matrix deposition and mineralization. In our 
study, we observed that re-exposure of differentiating PMSCs to higher oxygen 
tension in room air led to a more robust PMSC differentiation. 
 
The role of the IGF-IR in osteoblast differentiation (36) and in in vivo bone 
development (37, 51) is well recognized. However, the role of the insulin receptor 
is unknown. The IR has two isoforms IR-A and IR-B and it was demonstrated that 
IR-B is abundantly expressed in differentiating MSCs and mature osteoblasts 
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than IR-A which was abundantly expressed in proliferating cells (52). In this 
study, we showed that the IR might play a role in the differentiation process of 
PMSCs opposite to the expression of IGF-IR. This finding suggests that 
differentiating osteoblasts expresses higher IR levels to accommodate the higher 
energy demand in differentiating condition and utilizing more glucose for 
metabolism, especially via IR-B signaling which is enhanced by IGF-I.  
 
It was shown previously that signaling through IGF-IR in MSCs during 
differentiation is regulated by PI3K/AKT, and not MAPK, signaling (in a positive 
feedback loop) to inhibit apoptosis of osteoblasts (51). In this study, we showed 
that the inhibition of PI3K caused a significant reduction in pluripotency markers 
(OCT4 and SOX2) and osteogenic markers (RUNX2 and OPN), suggesting that 
PI3K is required not only to maintain multipotency but also to regulate PMSC 
differentiation. Interestingly, MEK/ERK signaling may also play a role in low 
oxygen tension by reducing the levels of RUNX2 and OPN as they were elevated 
by inhibiting MEK1/2, suggesting a possible role for MEK1/2 to suppress 
osteogenic differentiation.  
 
In conclusion, PMSCs successfully differentiate towards the osteogenic lineage, 
as an alternative source for MSC other than the more popular bone marrow MSC 
for tissue regeneration therapy. PMSC preconditioning in low oxygen tension and 
the use of IGFs (mainly IGF-I) to stimulate PMSCs is promising strategy to 
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generate osteogenic progenitor cells for tissue regeneration therapy for bone 
deficiencies. However, whether this strategy will enhance successful engraftment 
for the regenerative therapy in OI or bone fractures will require studying in animal 
models. 
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Appendix 3 
 
 
 
 
 
 
 
 
 
FIGURE S4.1. PMSC proliferation is more active in low oxygen tension 
regardless of the differentiation conditions. PMSCs were cultured for in non-
differentiation or osteogenic differentiation conditions containing 2% FBS in room 
air or low oxygen levels. Treatments were stopped after 3, 7, and 14 days for cell 
counting using a hemocytometer. (Two-Way ANOVA, P<0.05, n=6, * = significant 
difference between room air and low oxygen tension, # = significant difference 
between day 3 and day 7 and 14). 
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Appendix 3 
 
FIGURE S4.2. Inhibition of MEK1/2 and PI3K inhibits the phosphorylation of 
ERK1/2 and AKT. PMSCs were treated over 48-hrs period the time between 
media changes during a regular PMSC differentiation course. Treatment was 
stopped after 3, 6, 12, 24, and 48 hrs after inhibition by adding (5 μM) U0126 or 
(10 μM) LY294002 in presence of 2% FBS. Levels of p-ERK and p-AKT as 
shown in the immunoblots were normalized to total kinase levels and β-Actin, a 
protein loading control. (Two-Way ANOVA, P<0.05, n=4, a = significant 
difference by the presence of the inhibitor over time). 
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FIGURE S4.3. Inhibition of MEK1/2 and PI3K affects ERK1/2 and AKT 
signaling in PMSCs. PMSCs were cultured for 14-days in non-differentiation or 
osteogenic differentiation conditions containing 2% FBS in room air or low 
oxygen levels. During the 14 days, a continuous exposure to (5 μM) U0126 or 
(10 μM) LY294002 containing media was changed every 48-hrs. Treatments 
were stopped at 14 days and immunoblots were used to detect levels of ERK1/2 
and AKT changes induced by signaling inhibition. Quantification levels were 
normalized to total kinase level and β-Actin, a protein loading control. (Two-Way 
ANOVA, P<0.05, n=3, * = significant difference between room air and low oxygen 
tension, # = significant difference by adding the inhibitor, X = significant 
difference between differentiation and non-differentiation conditions). 
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FIGURE S4.4. Effect of MEK1/2 and PI3K inhibitors on PMSC viability 
during differentiation. PMSCs were cultured for 14-days in non-differentiation 
or osteogenic differentiation conditions containing 2% FBS in room air or low 
oxygen levels. During the 14 days, a continuous exposure to (5 μM) U0126 or 
(10 μM) LY294002 containing media was changed every 48-hrs. Treatments 
were stopped at 14 days and cell viability was measured by WST1 reagent 
assay. (Two-Way ANOVA, P<0.05, n=4, * = significant difference between room 
air and low oxygen tension). 
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5.1. Summary and Perspectives 
This study provides an insight into the understanding PMSC fate determination 
by IGFs and low oxygen tension. We found that low oxygen tension, a 
physiologic oxygen tension in stem cell niches in vivo, can regulate PMSC fate 
(multipotency or differentiation) in the presence of IGFs. First, low oxygen tension 
was found to enhance the IGF-I facilitated proliferation and multipotency 
response depending on PMSC gestational age (Chapter One). Second, low 
oxygen tension was found to enhance IGF-II expression and maintain PMSC 
multipotency by signaling via both the IGF-IR and the IR (Chapter Two). Lastly, 
low oxygen tension was found to inhibit the IGF-I stimulated osteogenic 
differentiation and maintain PMSC in a higher stemness state (Chapter Three). 
 
In this study, maintaining stem cells in low oxygen tension and improved the 
stemness possibly by mimicking the in vivo conditions. The manipulation of the 
IGF receptors (IGF-IR, IR and HR) signaling by IGFs in a concentration and time-
dependent manner was important to understand the stem cell behaviour. IGF-II, 
more than IGF-I, maintained a higher multipotency state in low oxygen tension, 
whereas IGF-I, more than IGF-II, improved the differentiated state of PMSCs in 
higher oxygen tension (room air). Also, low oxygen tension maintained a higher 
multipotent state even in differentiation-promoting culture conditions. Therefore, 
these results have implications for (1) defining the placental microenvironment 
during development that maintains PMSCs in vivo in a multipotent state; and (2) 
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identifying the molecular mechanisms underlying these microenvironmental 
changes in vitro in PMSCs to maintain multipotency or differentiation. We 
demonstrated in this study that during placental development, low oxygen 
tension, gestational age and IGF-axis signaling, can define the in vivo conditions 
that determine stem cell fate (multipotency or differentiation).  
 
5.1.1. The microenvironment is a major determinant of stem cell fate 
changes in vivo and in vitro 
5.1.1.1. Gestational Age 
Placental mesenchymal stem cells (PMSCs) used in this study were isolated 
from chorionic villi of preterm (11–13 wks) and late third trimester (37–39 wks) 
human placentae. In vivo, during chorionic villi formation, fetal mesenchyme 
migrates into primary villi at early gestation between 5th and 7th weeks, until the 
12th week of gestation when terminal villi are formed, and become the majority of 
villous type at term gestation (1, 2). Chorionic villi have the highest abundance of 
mesenchymal cells (undifferentiated and differentiated) that decreases with 
gestation; they are still found in term placentae but only 1% of total tissue by 
volume (3). This was described as a thinning that occurs to the stromal layer, 
hence a decreased number of mesenchymal tissue cell populations per section 
of chorionic villi (4). Placental gestational age can therefore be a determining 
factor in the abundance of PMSC isolated and colony formation capacity as they 
originate from the mesenchymal stromal layer of the chorionic villi. As 
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demonstrated by increased expression of stem cell markers, the higher 
proliferation capacity and earlier osteogenic differentiation changes, preterm 
PMSCs may have different characteristics and a more primitive state than term 
PMSCs. Although, both populations of PMSCs can proliferate in response to 
IGF-I and low oxygen tension and can differentiate into all lineages obtained by 
PMSCs. This can be naturally occurring in vivo by the changing 
microenvironment (gradual increase in oxygen tension and growth factor levels) 
of the chorionic villi with gestation to program stem cells; therefore PMSCs show 
distinct response to the same stimulation condition of IGFs and low oxygen 
tension in vitro. Thus, advancing in gestation can lead to some of the differences 
in the PMSC multipotency state and differentiation potential that should be 
considered when isolating PMSCs from the placenta.  
 
Low oxygen tension was shown to narrow the differences between the two types 
of PMSCs that were seen in room air of which term PMSCs could regain higher 
stemness and an increased proliferation level comparable to preterm PMSC. 
Hence, maintaining PMSCs in low oxygen tension in self-renewal supportive 
conditions is permissive to maintain stem cell markers, regardless of 
developmental stage of PMSCs. Also, preterm PMSCs were more responsive to 
IGF-I and IGF-II stimulation than term PMSCs. However, as shown previously, 
first trimester placenta provides a valuable source of MSCs which have greater 
expansion potential than adult bone marrow MSCs and are an excellent source 
for therapeutic application (5). Likewise, term human placenta is an abundant 
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source of chorionic villi MSCs and to have a high therapeutic potential as these 
cells can differentiate into the three germ layer cells (6). However, this is the first 
study to put into perspective the comparison of preterm and term PMSC 
multipotency control. Overall, the human placenta at different gestation is an 
excellent source of MSCs that may have different capacities due to the different 
microenvironment in vivo. 
 
5.1.1.2. Low Oxygen Tension  
The changing extracellular microenvironment is a major factor to regulate stem 
cell proliferation and differentiation in many developing tissues, including the 
placenta. Oxygen tension doubles between the first and second trimesters from 
about 18 mm Hg to 40 mm Hg, and then gradually increases to approximately 60 
mm Hg and maintained up to the third trimester (7, 8). This oxygen gradient is 
created starting at the first trimester of pregnancy (higher at the endometrium 
compared with fetal stromal layer) by the undeveloped fetoplacental circulation, 
resulting in low oxygen tension conditions, which is necessary for early 
development (9). In fact, blood flow from the spiral arteries into the intervillous 
space is prevented by the endovascular trophoblasts until the 12th week of 
gestation, to protect the early embryo from the excessively high oxygen levels 
(10). Therefore, preterm PMSCs naturally reside in low oxygen tension 
conditions compared to the later gestation PMSCs, and hence may adapt better 
to low oxygen tension conditions in vitro than term PMSCs.  
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The hypoxia inducible factor (HIF) system is activated more in early pregnancy. It 
is an upstream activator of VEGF, which is highly expressed in early gestation 
and decreased by third trimester, a stage when the placenta is well vascularized 
and less hypoxic (9). HIF-1α and HIF-2α expression are increased during the first 
trimester, peaking between 7-10 wks of gestation and declining thereafter with 
development having the lowest levels at term gestation (11). This HIF signaling 
initiates the development of the fetoplacental circulation by increasing 
proliferation of trophoblast cells and stromal mesenchymal cells and forming new 
capillaries, in the oxygen deprived stromal layer. This is triggered by growth 
factors, such as b-FGF, VEGF and PlGF (12). In this microenvironment, IGF-II 
and not IGF-I, is a major signaling factor targeted directly by HIF-1 regulation to 
induce an increased transcription (13, 14), leading to increased IGF-II levels in 
early gestation. In turn, IGF-I and IGF-II stimulation can stabilize HIF-1α and HIF-
2α (11). Therefore, low oxygen tension and IGFs may have a crosstalk with a 
positive feedback mechanism. In our PMSCs, low oxygen tension upregulated 
IGF-II expression at the mRNA level even in presence of IGF-I or IGF-II, 
mirroring the in vivo microenvironment of the placenta.  
 
5.1.1.3. Insulin-like Growth Factor System 
The PMSCs we studied are derived from chorionic villi and they reside in the 
perivascular region of the fetal compartment where the exchange of nutrients, 
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oxygen and waste between the mother and the fetus. Therefore, they are in 
contact with factors from both the fetal and maternal circulations, and hormones 
and factors synthesized by the syncytiotrophoblasts, cytotrophoblasts and the 
chorionic mesoderm. IGF-I and IGF-II are synthesized in the placenta by the 
chorionic mesoderm (where PMSCs reside), where IGF levels do not relatively 
change during gestation across the three trimesters (15). In the fetus, IGFs are 
one of the most abundant growth factors in the circulation that are just 
downstream signaling of the GH axis at the level of organs, tissues and cells 
(16). In the placenta, a pituitary GH variant, the placental lactogen/chorionic 
somatomammotropin, functions in a paracrine fashion to upregulate IGF 
expression and sustain an increased growth in the placenta (17). In the fetus, the 
liver is the major source of circulating IGFs, whereas in the placenta, as in many 
extra-hepatic tissues, IGFs are expressed in a paracrine/autocrine fashion 
regulated in part by placental GH (16, 18). It has been shown that IGF-I and IGF-
II paracrine/autocrine signaling were required for first trimester placental primary 
fibroblast increased survival, proliferation, and migration and decreased 
apoptosis (19). Our PMSCs express their own IGFs, both IGF-I and IGF-II, which 
promoted localized paracrine/autocrine cellular growth as was shown in serum 
free growth conditions.  
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The ability of IGF-I and IGF-II to maintain PMSC multipotency or 
differentiation 
The importance of IGF function in the human placenta stems from their role in 
mediating increased growth, reduced apoptosis, and induced differentiation of 
the different cells of the chorionic villi (20, 21). Placental development is 
dependent on IGF and IGF receptor expression, however, the relative role of 
IGF-I and IGF-II can vary depending on spatial and temporal expression during 
pregnancy (22). The cord blood IGF-I concentration, and not IGF-II, is correlated 
with birth weight fetal growth restriction in humans, whereas the placenta is more 
correlated with IGF-II (23). This is similar to the mouse in which Igf2 knockout 
severely reduced placental growth (24). In the human placenta, IGF-II mRNA is 
expressed in the villous mesenchymal core, where PMSCs reside, at all three 
trimesters (22). IGF-II plays a role in migration, proliferation, and decrease 
apoptosis of extravillous- and cyto-trophoblasts in the placenta (11), whereas 
IGF-I is implicated in later gestation, and is involved in cytotrophoblast 
differentiation. In PMSCs, we showed that both IGF-I and IGF-II induced a 
concentration and a time response increased proliferation in low oxygen tension 
and that IGF-I enhanced spontaneous and osteogenic directed differentiation.  
 
IGF Receptor Expression 
In the placenta, both IGF-IR and the IR are expressed mainly in the microvillous 
membrane of the proliferating cytotrophoblasts in the first trimester, with a switch 
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to an expression in the basal membrane facing fetal circulation at term gestation 
(15). However, there is no information on the localization of the IGF-IR or IR in 
PMSCs in the placenta during different gestational ages. In PMSCs, IGF-IR and 
IR are highly expressed in preterm PMSCs that decline with gestational age. This 
higher expression level of both receptors correlates with the higher IGF-II levels 
expressed at the low oxygen tension conditions at early gestation. The role of the 
IR in placental growth was suggested by the dual knockout mouse for Igf2 and 
Igf1r that was more severely growth restricted than Igf1r knockout alone, 
indicating that IGF-II can signal through another receptor to mediate placental 
growth (24); this can also be the case in human placenta. IR signaling (via IR-A) 
was confirmed to mediate placental growth via IGF-II signaling in early gestation 
(25); the IGF-IR is expressed abundantly by the middle of the first trimester—
becoming of higher affinity to IGFs with advanced gestation (26). This 
consequently spares the most abundant IGF-II signaling for the IR-A rather than 
IGF-IR during early gestation. We have observed the dual expression of IGF-IR 
and IR in PMSCs, which can favour the formation of hybrid receptors IGF-IR/IR 
that preferentially binds to IGFs rather than insulin. In the human placenta, 55% 
of the IGF-IR is assembled in the hybrid form to specifically bind IGF-I than 
insulin (27). IR-A and IGF-IR/IR-A (HR-A) are upregulated in various cancers 
(breast, thyroid, myosarcoma, osteosarcoma, cervical and prostate) to mediate 
more aggressive malignant cancer forms (28). Therefore, HR-A can be involved 
to maintain a more naïve state of cancer stem cell development. A similar 
biological function may be present in PMSCs in vivo. 
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PMSC fate is likely determined by the differential signaling due to receptor 
affinity, choice of receptor (IGR-IR, IR, hybrid IGF-IR/IR) and the combination of 
downstream receptor signaling cascades. At the receptor level, low oxygen 
tension increased IR-A as well as IGF-IR expression even in presence of high 
levels of IGFs. IGF-I and IGF-II may utilize different signaling molecules as IGF-
IR has greater affinity to IGF-I than IGF-II, and IR-A has greater affinity to IGF-II 
than IGF-I (29). Therefore, the increased expression of pluripotency triad 
transcription factors by IGF-II maybe transduced via IR-A. Also, in PMSCs, IR 
has played a role in increasing proliferation in low oxygen tension in addition to 
IGF-IR. This could be because IR-A, which unlike IR-B, can induce a mitogenic 
signal similar to IGF-IR suggesting that the increased abundance of IR or HR-A 
in low oxygen tension can induce proliferation. Therefore, PMSCs cultured in low 
oxygen tension can utilize different signaling cascades to enhance PMSC 
proliferation and multipotency.  
 
IR was also increased in differentiating PMSCs towards the osteogenic lineage in 
room air but not in low oxygen tension. A recent report showed that IR increases 
with a higher ratio of IR-B to IR-A in differentiating osteoblasts (30). Unlike IR-A, 
which mediates mitogenic actions involved in increased cell proliferation, 
atherosclerosis and cancer, IR-B is responsible for metabolic action to facilitate 
metabolism, cell differentiation and increased longevity (28). Hence, IR-A is 
required for stem cell self-renewal while IR-B is required following differentiation. 
In osteogenesis, a metabolic switch is required for a complete osteogenic 
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differentiation to upregulate mitochondrial count and cellular aerobic respiration, 
which is obscured by low oxygen tension (31). Therefore, an upregulation of IR-B 
may increase insulin signaling for glucose uptake which is required as an energy 
source in aerobic respiration for increased ATP production. 
 
Kinase Signaling 
We demonstrated that ERK1/2 and AKT are important downstream mediators of 
IGF signaling in stimulating proliferation and multipotency of PMSCs in vitro that 
may be applicable in vivo. ERK1/2 is important in mediating cell proliferation and 
growth, whereas AKT is important in cell survival and metabolism. These two 
signaling cascades are important for regulating PMSC proliferation and 
maintaining multipotency. How these two signaling cascades interact in 
regulating stem cell multipotency at the molecular level has not been delineated. 
A recent identification of 14 phosphorylation sites on OCT4, away from the DNA 
binding site, revealed three putative phosphorylation sites for ERK2 at S111, 
T118, and S355 (32) which may provide a direct link to IGF signaling in stem 
cells; however, the role of OCT4 phosphorylation is not yet clear. Also, ERK2 has 
been shown to interact directly with chromatin at the SOX2 promoter regions to 
maintain its transcription (33); in addition, ELK1 (ERK2 downstream substrate) 
can interact with the repressive complex polycomb group protein complex 2 
(PRC2) to repress differentiation genes and therefore can maintain ESC 
pluripotency (33). On the other hand, AKT has been shown to interact directly 
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with EZH2, a component of PRC2, to phosphorylate it on Ser-21 (34). Thus, IGFs 
can stimulate phosphorylation of EZH2 via AKT pathway and reduce the capacity 
of PRC2 to trimethylate histone H3K27 in promoter regions of OCT4 and 
promote the de-repression of the OCT4 promoter transcription and maintain 
multipotency (unpublished data). 
 
During differentiation, MEK1/2 is important for osteoblast differentiation and 
skeletal development, as it is required for RUNX2 phosphorylation and 
transcriptional activity (35, 36). Also, the PI3K plays an important role in 
osteogenic differentiation (37). However, the role of PI3K and MEK in facilitating 
and inhibiting MSC differentiation is still controversial (37). In a previous study, 
PI3K was shown to be essential in mediating osteoblast differentiation of MSCs, 
while MEK repressed MSC differentiation towards the osteogenic lineage (38). In 
addition, IGF-I expression in MSCs increased osteogenic differentiation for bone 
repair, which was mediated via IRS1-PI3K (39). In our PMSCs, both PI3K and 
MEK were required for osteogenic differentiation in room air, and their inhibition 
repressed complete differentiation. The role of PI3K was greater than MEK in 
mediating differentiation in both low oxygen tensions and room air, while in low 
oxygen tension MEK showed a role in repressing differentiation. Therefore, low 
oxygen tension can change the role of signaling kinases in mediating PMSC 
differentiation. However, these signaling differences still need investigation to 
determine the mechanisms of how PI3K and MEK can mediate the differentiation 
process of PMSCs in low oxygen tension. 
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5.1.1.4. PMSC Fate Changes 
Low oxygen tension improved the stemness level of PMSCs (increased OCT4, 
SOX2 and NANOG expression) and increased proliferation. The enhanced stem 
cell gene expression can be mediated via HIF-2 direct interaction with all three 
pluripotency genes to increase transcription (40, 41). OCT4, SOX2 and NANOG 
gene expression was upregulated by longer stimulation time by IGFs but 
decreased by increased IGF concentration. In our study, we mainly focused on 
OCT4, the master regulator of pluripotency. OCT4 mutation/loss is embryonic 
lethal (42), whereas ectopic overexpression causes dedifferentiation in somatic 
cells (43). In MSCs, ectopic expression of OCT4 increased proliferation and 
maintained cell morphology during prolonged passaging and inhibited 
spontaneous differentiation (44). In PMSCs, IGF-I and IGF-II increased OCT4 
expression (more with IGF-II), confirming that IGFs can enhance stemness in 
combination with low oxygen tension. 
 
MSCs differentiate into the mesodermal lineage and also can differentiate 
towards endodermal and ectodermal lineages; however, this phenomenon of 
transdifferentiation is still controversial in vivo (45). We have found that PMSCs 
can differentiate towards the mesodermal lineage (adipose, osteogenic, 
endothelial, myogenic), and ectodermal cells (neuron-like cells expressing 
Nestin). MSCs transdifferentiation occurs due to MSC heterogeneity, which is 
referred to a mixture of progenitor cells at different stages of commitment to 
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multiple lineages (45). In vivo, MSC plasticity is needed to adapt to varying 
stressors and microenvironmental demands to repair tissue damage (46). 
Therefore, MSCs express genes from at least two germ layers and pluripotency 
triad genes demonstrating a “multi-differentiation” potential awaiting the fate 
restriction signal (47). Therefore, differentiation of MSCs is not a simple on/off 
switch but is regulated through transcription of specific genes depending on the 
microenvironment. Osteogenic differentiation is a classical mesodermal lineage 
originated from the MSC in the bone marrow. Therefore, osteogenic 
differentiation of PMSCs, which does not normally occurs in vivo, demonstrates 
PMSC plasticity.  
 
In the placenta, PMSCs can differentiate into four mesodermal lineage cells: 
macrophage-like mesenchymal cells, haemangioblastic cords, pericytes and 
stromal fibroblasts (48), where IGFs and low oxygen tension can play an 
important role (49, 50). In this study, we show that PMSCs can differentiate into 
mesodermal osteoblasts expressing RUNX2, osteopontin, and alkaline 
phosphatase. Moreover, differentiated osteoblasts deposit bone matrix and stain 
positive for calcium deposition. During this process, room air was a major 
facilitator of differentiation, while low oxygen tension repressed this effect. Low 
oxygen tension increased OCT4 and SOX2 and lowered RUNX2 and 
osteopontin. IGFs facilitated an earlier commitment towards osteogenic 
differentiation with higher levels of OCT4 and SOX2. However, IGF-I was more 
potent than IGF-II to enhance osteogenic differentiation.  
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The ratio between OCT4 and SOX2 is important for mesodermal differentiation 
with lower SOX2 (51) and higher OCT4 (52, 53). In PMSCs, OCT4 levels did not 
decrease post differentiation and was enhanced by IGFs; however, SOX2 levels 
were decreased confirming mesodermal differentiation. In fact, OCT4 
overexpression in MSCs enhanced adipogenic and chondrogenic differentiation 
by increasing differentiation markers and promoting the complete differentiation 
morphology (44). Therefore, OCT4 might be required for osteogenic 
differentiation. SOX2 overexpression inhibits osteoblast differentiation by 
promoting higher proliferation (54). Therefore, the reduction in SOX2 levels in 
osteogenic differentiation can also confirm PMSC differentiation. The 
coexpression of RUNX2 and osteopontin is a marker of progenitor osteoblasts 
formation (55). We found that an increased RUNX2 expression occurs early in 
osteogenic differentiation, while osteopontin levels were increased by the end of 
differentiation period confirming osteogenic commitment. 
 
5.2. Overall Conclusions 
In this study, we showed that the human placenta is a valuable source of 
mesenchymal stem cells that can be expanded and differentiated in vitro by 
manipulating the surrounding microenvironment. Low oxygen tension is the major 
regulator of stemness by enhancing PMSC proliferation and pluripotency gene 
expression. As summarized in Figure 5.1, although PMSCs from different 
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gestations respond differently to IGF stimulation, low oxygen tension enhances 
PMSC proliferation and pluripotency gene expression levels. Low oxygen tension 
activates ERK1/2 signaling, while IGFs activates AKT signaling of which both are 
required to maintain PMSC proliferation and multipotency. PMSC fate changes 
were differently mediated by IGFs: IGF-I induced differentiation and IGF-II 
maintained higher PMSC stemness. Low oxygen tension decreases spontaneous 
differentiation and inhibits PMSC osteogenic differentiation but can enhance 
differentiation if re-exposed to room air. Therefore, to maintain PMSCs in 
multipotent state, PMSCs from different gestations should be cultured under IGF-
II and low oxygen tension conditions, whereas, to differentiate PMSCs to 
progenitor cells, PMSCs should be cultured under IGF-I and room air conditions.  
 
Overall, mimicking the in vivo microenvironment of placental mesenchymal stem 
cells can improve the in vitro culture conditions for tissue regeneration therapy. 
And also, priming PMSCs by IGFs and preconditioning by low oxygen tension 
are important steps to improve PMSC growth, multipotency, and differentiation 
that can improve PMSC survival and differentiation potential for tissue 
regeneration.  
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Figure 5.1. stem cell fate in low oxygen tension and insulin-like growth 
factor conditions. PMSCs are isolated from preterm and term gestations. To 
maintain PMSCs in a multipotent state, low oxygen tension can activate 
endogenously the ERK1/2 pathway while IGFs activate the AKT signaling 
pathways. Both signaling pathways are indispensible for PMSC proliferation and 
pluripotency gene expression. PMSC spontaneously differentiate towards the 
osteogenic lineage if grown in room air conditions, whereas, self-renewal is 
maintained if PMSCs are maintained under low oxygen tension conditions. IGF-I 
is shown to drive PMSC differentiation, while IGF-II can maintain PMSC 
multipotency and higher stemness state. Low oxygen tension inhibits PMSC 
osteogenic differentiation by maintaining higher pluripotency gene levels and 
lower osteogenic differentiation proteins and transcription factors. 
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5.3. Limitations and Future Studies 
A comparative study of MSCs from chorionic villi of different gestations and 
umbilical cord blood with bone marrow and embryonic stem cells can improve 
our understanding of the hierarchy of multipotency of stem cells from different 
placental sources. Information about IGF-I or -II concentration in the human 
placenta during different gestational ages is lacking; however, we inferred from 
the concentration of either ligand in the umbilical cord blood to be 100 ng/mL and 
300 ng/mL of IGF-I or -II, respectively. We used 10, 50, up to 100 ng/mL of either 
IGF-I or -II; as the highest reached by IGF-I as measured by the umbilical cord 
blood to equalize the molecular concentration of both IGFs; however, we may 
need to increase IGF-II concentration to 300 ng/mL, mimicking the in vivo 
conditions, to see more physiological effect at term gestation placenta 
development. Also, the combination of both IGFs in one treatment may delineate 
different effects on PMSC multipotency or differentiation as both IGFs coexist in 
vivo.  
 
For further experimentation, it is important to synchronize cells by serum 
deprivation before the treatment by IGFs. Serum deprivation was not used here 
as we judged that in a physiological condition in vivo no withdrawal of all growth 
factors and cytokines is possible all at once. Monitoring the cell surface markers 
CD73, CD105, CD117 expression during IGF stimulation will give an indication of 
how multipotency changes during stimulation time in proliferation or 
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differentiation conditions. An inhibition by siRNA or an ectopic expression of 
OCT4 would delineate the role of OCT4 in response of IGFs in self-renewal and 
differentiation conditions. OCT4 localization is important for its function; therefore 
nuclear vs. cytoplasmic fractionation and immunocytochemistry experiments 
would be essential to show the dynamics of OCT4 during differentiation. This 
becomes of importance when the high expression of OCT4 in differentiation 
conditions is due localization and not function.  
 
The use of a phospho-kinase array could specify the interacting adaptor and 
signaling protein with the IGF-IR upon stimulation by IGFs under the two different 
oxygen tensions. Knockdown studies of IGF-IR or IR can improve the 
understanding of receptor role in mediating PMSC differentiation and the 
prolonged proliferation effect in IGF and oxygen tension changes. Specific 
inhibitors for ERK1/2 and/or AKT could specify the role of these two kinases in 
IGF mediated proliferation and differentiation effects as MEK1/2 and PI3K have 
more targets than just ERK1/2 and AKT. Also, using dominant negative kinases 
can help identify the role ERK1/2 and AKT in the differentiation process. As IGF-
IR and IR-A/-B expression change during differentiation, it is important to use a 
real-time PCR to identify the receptor level changes and determine whether 
expression changes are mediated by IGFs and low oxygen tension. 
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Extending the differentiation protocol to 21 or 28 days can improve and complete 
the osteogenic differentiation and perhaps lower the OCT4 expression to minimal 
levels. This can confirm full mineralization correlating with higher levels of 
osteocalcin and loss of RUNX2 and osteopontin in the mature osteoblast 
phenotype. In line with RUNX2 phosphorylation, we need to understand the 
phosphorylation changes induced by low oxygen tension and IGFs upon 
differentiation stimulation.  
 
Besides osteogenic differentiation, we can study the effect of low oxygen tension 
on chondrogenic differentiation, which is known as an avascular tissue and 
requires low oxygen tension. Also, as PMSCs naturally develop into endothelial 
cells, differentiating PMSCs into endothelial cells will improve our understanding 
of the natural development of chorionic villi during gestation. 
 
Changes in PMSC fate triggered by the microenvironmental factors can cause 
reprogramming effects that can change the epigenetic profile of initial genes. It is 
of interest to understand the epigenetic changes by IGFs and low oxygen tension 
to maintain multipotency or mediate differentiation. DNA methylation analysis by 
bisulfite sequencing or enrichment of variant histones by ChIP analysis, we can 
identify the state of OCT4, SOX2 and NANOG promoter regions and understand 
the changes upon differentiation towards the osteogenic lineage at RUNX2 
promoter. 
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The optimal use of PMSCs is for tissue regeneration therapies. Priming PMSCs 
with IGFs and preconditioning with low oxygen tension should be used into 
animal models to prove the beneficial effects of these two conditions on PMSC 
engraftment and survival. Such models can include pancreatic injury or brain 
ischemia. Also, with osteogenic differentiation abilities of PMSCs, we can study 
the benefits of either using fully multipotent PMSCs or osteoblast progenitor cell 
for engraftment into animal model of osteogenesis imperfecta; and whether low 
oxygen tension and IGFs can improve bone gain and total growth.   
 
5.4. Significance 
The manipulation of PMSCs by IGFs and low oxygen tension can help 
understand stem cell development in vivo and define the in vitro cell culture 
conditions for optimal use in tissue regeneration therapies. 
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